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ABSTRACT OF DISSERTATION 
 
 
 
FUNCTIONAL IMPACT OF ANGIOTENSINOGEN SPECIFIC DOMAINS ON 
ANGIOTENSIN II-MEDIATED FUNCTIONS 
 
Angiotensinogen (AGT) is the only substrate for all angiotensin peptides in the 
renin angiotensin system (RAS). Cleavage of AGT by renin is a rate-limiting step of 
angiotensin peptides productions in the RAS and regulates angiotensin peptides-associated 
pathophysiological functions. Only ten N-terminal residues are cleaved by renin and the 
functions of remaining part of AGT protein, which is called des(angiotensin I)AGT, remain 
unclear. Despite of pivotal roles of AGT in the RAS, studies related to how AGT is 
metabolized and how des(angiotensin I)AGT regulates AGT functions or AngII-mediated 
functions are limited. 
Renin cleavage of AGT shows species specificity. It has been reported that residues 
in N-terminus of AGT surrounding renin cleavage site play important roles of affecting 
renin activity in vitro by using synthetic peptides. However, there is no in vivo evidence 
showing the effects of N-terminal residues in renin cleavage of AGT and consequently 
AngII-mediated functions, such as blood pressure and atherosclerosis. In this study, we 
compared expressions of AGT proteins by adeno-associated viral (AAV) vectors encoding 
human AGT or mouse AGT with Leu11Val and Tyr12Ile mutations which mimics two 
residues at the same position in human AGT to determine whether substitution of these 
residues regulated AngII-mediated functions. All mice were LDL receptor-/- mice. 
Hepatocyte-specific AGT deficient (hepAGT-/-) mice were injected with AAVs encoding 
null AAV, human AGT AAV or mutated mouse AGT (L11V;Y12I). hepAGT+/+ littermates 
injected with null AAV as positive controls. Expression of human AGT did not affect 
endogenous mouse AGT expression, blood pressure and atherosclerosis in hepAGT-/- mice. 
In a subsequent study, expression of L1V;Y12I AGT significantly increased plasma AGT 
concentration, blood pressure and atherosclerosis, showing that replacement of L11 and 
Y12 to V11 and I12, respectively, in mouse AGT does not affect renin cleavage, blood 
pressure, and atherosclerosis in LDL receptor deficient mice. 
AGT has been reported to have both AngII-dependent and -independent functions. 
In our previous publication, we found two highly conserved regions, the β-sheet and loop 
region, on the surface of AGT which are distal to renin interacting face, and showed that 
these two highly conserved regions might have renin-independent roles. Moreover, we 
demonstrated that AGT and megalin interactions predispose animals to atherosclerosis. 
Thus, in this study, we investigated whether these two highly conserved regions affect 
AngII-mediated functions thorough influencing AGT interaction with megalin. Firstly, we 
determined the roles of the loop region in the interaction of AGT with megalin in vitro. All 
mice were LDL receptor-/- background. However, repopulation of mouse AGT with single 
nucleotide mutation on the loop region, triple nucleotide mutations on the β-sheet or the 
loop region, and replacement of whole conserved sequences in the loop region with a GA 
linker did not change blood pressure and atherosclerosis in hepAGT-/- mice, which is 
associated with plasma AGT concentration. Interestingly, mutations on both the β-sheet 
     
 
and loop region inhibited plasmas AGT level, blood pressure and atherosclerosis, showing 
the β-sheet and loop region synergistically regulate AGT production and consequently 
affect AngII-mediated functions in hepAGT-/- mice. 
Taken together, residues in AGT have different biological effects which regulates 
angiotensin-associated functions. 
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CHAPTER 1. LITERATURE REVIEW – CRITICAL ROLES OF ANGIOTENSINOGEN IN ANGII-
MEDIATED FUNCTIONS 
This chapter provides an introduction to relevant concepts of my research works in 
this dissertation. This dissertation discusses the possible roles of specific amino acids of 
AGT in AGT metabolism and AngII-mediated functions. 
1.1 Introduction 
The renin angiotensin system (RAS) is a well-known hormone system regulating 
body fluid and blood pressure [1, 2]. Angiotensinogen (AGT), the only substrate of the 
RAS to produce all angiotensin peptides, is converted into angiotensin I (AngI) by renin. 
AngI is then converted to angiotensin II (AngII) by angiotensin-converting enzyme (ACE). 
AngII is an octapeptide which mediates angiotensin II receptor type 1 (AT1)-mediated 
physiological and pathological functions. (Figure. 1.1). Human AGT is 452 amino acids 
long and mouse AGT is 453 amino acids long. Since the pivotal roles of AGT in the RAS, 
AGT regulates AngII production and AngII-mediated functions, such as atherosclerosis 
and hypertension.  
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Figure 1.1 Angiotensinogen is the only substrate of the renin angiotensin system. 
 
 
Atherosclerosis, a disease caused by plaque building-up inside arterial wall, is a 
leading risk factor of many cardiovascular diseases [3]. It has been reported by many 
groups that the RAS is involved in the pathogenesis of atherosclerosis [4-6]. In the RAS, 
AngII is a major factor contributing to vascular pathology by direct and indirectly affecting 
vascular wall and various types of cells (Figure 1.2) [6-8]. AngII induces oxidative stress 
[9-11], inflammatory cytokines and adhesion molecules production [12, 13], LDL 
oxidation and uptake [14, 15], and endothelial dysfunction [16]. For example, AngII 
infusion (500 ng/kg/min) for 28 days increased cholesterol accumulation in atherosclerotic 
lesions in LDL receptor-/- mice [17]. AngII infusion (1000 ng/kg/min) for 28 days 
increased macrophage accumulation in atherosclerotic lesions and promoted severity of 
atherosclerosis in apoE-/- mice [6]. Inhibition of AngII production by blocking renin [18-
20] or ACE [21-24] attenuates atherosclerosis. In addition, AT1 receptor antagonism by 
AT1 receptor blocker or genetic knockout attenuates atherosclerosis in animals and human. 
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In animals, AT1 receptor antagonists, such as losartan [25-27], valsartan [28, 29] and 
irbesartan [30, 31], olmesartan [32] and telmisartan [33], significantly decreased intimal 
lesions in hypercholesterolemia-induced atherosclerosis in monkeys, rabbits or mice. 
AT1A receptor deficiency significantly reduces hypercholesterolemia-induced 
atherosclerosis in LDL receptor-/- mice [34, 35], which associates with the decrease in 
hypercholesterolemia-enhanced systemic AGT and angiotensin peptides [35]. AT1A 
receptor deficiency also attenuates vascular dysfunction and atherosclerosis in apoE-/- mice 
[36, 37]. In human, irbesartan attenuates inflammatory markers in premature forms of 
atherosclerosis [38] and inhibits MMP-induced plaque rupture by blocking COX-
2/mPGES-1 expression [39]. Losartan [40, 41] and olmesartan [42] significantly reduce 
intima-media thickness in patients with hypertension. Taken together, AngII-AT1 receptor 
pathway regulates and promotes the formation of atherosclerosis. 
 
 
Figure 1.2 Renin angiotensin system contributes to atherosclerosis. 
 
 
Reports show that the RAS elevates blood pressure in human and animals. In 
human, drug interventions to treat hypertension are well established. However, 
hypertension-related cardiovascular complications, such as left ventricular hypertrophy 
(LVH), are commonly seen in hypertensive patients. Angiotensin II receptor blockers 
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(ARBs), which have been widely used for lowering blood pressure in hypertensive 
patients, show beneficial effects on hypertension-related cardiovascular complications. 
For example, losartan not only reduced blood pressure but also prevented  more  
cardiovascular morbidity and death than atenolol, a β-blocker, did [43, 44]. Losartan 
reduced blood pressure, protected arterial structure as well as endothelial functions [45], 
and regressed myocardial fibrosis [46] in hypertensive patients . To better understand the 
roles of the RAS components in the regulation of blood pressure, inhibition of the RAS 
components was studied in animal models. For example, losartan, an AT1 receptor 
antagonist, blunted the blood pressure increase caused by diet-induced obesity in male 
Sprague-Dawley rats [47]. When administered either acutely or chronically, enalapril, an 
angiotensin converting enzyme inhibitor, decreased blood pressure in rats [48]. 
Angiotensin type 1a (AT1a) receptor-/- mice showed significantly decreased blood 
pressure [49].  
AGT is the only precursor of AngII. There is also evidence that AGT is associated 
with AngII-dependent vascular pathology and blood pressure regulation. In 
atherosclerosis, single nucleotide polymorphisms of AGT are associated with coronary 
atherosclerosis. For example, T704C [50], T174M [51, 52] and M235T [51, 53-55] of 
AGT are associated with coronary atherosclerosis in different populations. In addition, 
deficiency of plasma AGT significantly decreased atherosclerotic lesions in hepatocyte-
specific AGT deficient mice [56-59]. hypoAGT mice, which had greatly reduced AGT 
mRNA abundance in all tissues, also showed significant decrease in atherosclerosis and 
blood pressure [59]. Antisense oligonucleotides targeting AGT attenuated high blood 
pressure, atherosclerosis and many other diseases [60-62]. In hypertension, overexpression 
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of rat AGT increased plasma AGT concentration and blood pressure in mice [63]. Whole 
body AGT knockout mice, which had severe impact on neonatal survival rate and renal 
functions, showed hypotension [64]. Infection of adeno-associated viral vector encoding 
AGT antisense oligonucleotide in spontaneously hypertensive rats significantly decreased 
blood pressure with a short-term [65, 66] or a long-term effect [67]. Small  interfering  
RNAs  (siRNAs)  targeting  hepatic AGT  reduced blood pressure [68, 69], and inhibited 
preeclamptic phenotypes [70]. In summary, these findings reveal the important roles of 
AGT in AngII-mediated functions. 
1.2 Molecular characteristics of AGT 
1.2.1 AGT gene and protein structure 
AGT is present throughout vertebrate evolution and is conserved from lampreys to 
human [71]. Human AGT, which is localized on chromosome 1 and consists of 5 exons 
[72, 73], is 485 amino acids with a 33-amino acids signal peptide [74]. Mouse AGT, which 
is located on chromosome 8 and consists of 6 exons [75, 76], is 477 amino acids including 
a 24-amino acids signal peptide. AngI, 10 N-terminal amino acids, is cleaved from AGT 
and the remaining part of AGT which is called as des(AngI)AGT.  
 
1.2.2 Effects of conserved and non-conserved residues of AGT on AGT metabolism 
Amino acids determine gene expression and protein functions. There are many 
studies reporting amino acids of AGT, such as genetic variants and formation of disulfide 
bond, affect AGT expression and production as well as AGT-associated diseases. 
15 
 
 
1.2.2.1 Genetic variants 
Genetic variants have been showed to regulate AGT expression and associate with 
hypertension and other diseases. Two variants of the AGT gene, M235T and T174M, have 
been extensively studied and shown to be associated with hypertension [77-82] and other 
cardiovascular diseases [83-85] in certain populations, such as Japanese and Caucasians. 
For example, M235T of AGT predisposed to hypertension and associated with 
cardiovascular risk factors in Japanese [80], and also associated with pre-eclampsia [86].  
M235T of AGT was independently and significantly associated with coronary heart 
diseases in Caucasians [83]. A meta-analysis which included 127 studies published 
between January 1992 and March 2002 showed the association of M235T of AGT with 
plasma AGT concentration and risk of hypertension [87]. T174M of AGT was significantly 
associated with systolic blood pressure only in men in the Hutterite Brethren, a North 
American religious genetic isolate [88]. In addition, other gene polymorphisms of AGT, 
such as T704C are associated with cardiovascular diseases, including coronary 
atherosclerosis [50]. However, some studies showed that M235T or T174M of AGT might 
not be a risk factor for hypertension or coronary heart disease in some ethnic populations, 
such as Indian [89], East Anglian subjects of the United Kingdom[90], Chinese [91], 
African Caribbean [92], and African American [93].  
Genetic variants have been found to contribute to AGT production, which might be 
the reason causing hypertension and cardiovascular diseases. It was reported that higher 
frequency of T235 of AGT in black children had higher plasma AGT concentration than 
in white children [94]. Also, higher plasma AGT concentration was found in female 
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carrying M235T than in male in Lake Salt City [95]. To understand the causality between 
AGT gene with plasma AGT concentration and hypertension, genetic mice with zero- to 
four- copy of mouse AGT gene in normal chromosomal location were generated and tested. 
Plasma AGT concentration was gradually increased in a copy number-dependent manner, 
which positively related to blood pressure [96].  
These studies show that genetic variants of AGT, such as M235T and T174M 
determine AGT production and downstream AngII-regulated blood pressure as well as 
cardiovascular diseases based on gene frequency, gender, ages, and ethnics. 
 
1.2.2.2 Disulfide bond 
There are four cystines in AGT and two cystines (Cys18-Cys138 in human and 
Cys18-Cys137 in mouse) forming a disulfide bond are conserved among species [97, 98]. 
Cys18-Cys138 disulfide bond has been reported to involve in regulation of structure of  N-
terminus of AGT [97]. Zhou et al. (2010) reported that Cys18-Cys138 disulfide bond 
facilitated active site cleft of renin binding on N-terminus of AGT and consequently 
enhanced cleavage of AGT to release AngI by protein crystal structure analysis [99]. 
Moreover, they found that percentage of reduced form of AGT decreased which means 
oxidized AGT increased in pregnant women with preeclampsia, showing redox-switch of 
AGT regulates AngII production and hypertension. Rahgozar et al. [100] used another 
method, ELISA to measure plasma total and reduced AGT and confirm Zhou et al. results 
done by Western blot analysis. Rahgozar et al. in 2015 showed the same result that reduced 
AGT significantly decreased in pregnant women with preeclampsia. Most recently, 
Dahabiyeh et al. (2020) confirmed decreased ratio of oxidized AGT to total AGT in 
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pregnant women with preeclampsia by a mass spectrometry-based method [101]. However, 
repopulation of mutated AGT with lacking Cys18-Cys137 disulfide bond in hepatocyte-
specific AGT deficient mice did not affect blood pressure and atherosclerosis, showing 
that Cys18-Cys137 disulfide bond formation is not essential for AgnII production and 
AngII-mediated functions in mice [56]. In summary, disulfide bond formation might 
determine AGT metabolism and predisposes to hypertension in human, but not mice. 
 
1.2.2.3 Residues surrounding renin cleavage site 
AngI (amino acid position at 1- 10 of AGT) is highly conserved between species; 
however, amino acid residues adjacent to AngI is not conserved in species (Fig. 1.3). 
Therefore, N-terminal amino sequences of AGT has been assumed as the factor regulating 
the interaction of AGT to renin and catalytic activity of renin cleavage of AGT. It was 
reported that removal of tyrosine at C-terminal position 2 of renin cleavage site abolished 
synthetic substrate activity to hog renin [102]. Tewksbury et al. showed the potential effect 
of residue at position 3 at C-terminal side of renin cleavage site on Kcat/Km of renin [103]. 
Cumin et al. showed that N-terminal residues at position 11 to 14 play an important role 
of renin cleavage efficiency, especially 12’ Ile replaced by Tyr in human tetradecapeptide 
[104]. Replacement of residues at position 1 and 2 adjacent to renin cleavage site of human 
AGT to mimic the two residues at the same position of canine AGT significantly enhanced 
Kcat/Km of canine renin [105]. Moreover, amino acids at position 12 and 13 of human N-
terminus of AGT are seemed to affect the catalytic reaction of renin [106]. Although these 
show the important roles of amino acid residues adjacent to renin cleavage site in catalytic 
efficiency of renin and AngI production, these studies used synthetic peptides and in vitro 
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assays. Therefore, in vivo evidence, such as mouse study, is needed to investigate functions 
of amino acids around renin cleavage site in AGT metabolism. 
 
Figure 1.3 Amino acid sequence of N-terminus part of natural renin substrates. 
 
 
1.2.2.4 Conserved residues in des(AngI)AGT structure 
AGT is cleaved by renin to release 10 amino acids-long AngI and des(AngI)AGT 
which is the remaining part of AGT (98% of AGT). AngI is cleaved by ACE to produce 
AngII, which affects and regulates many physiological and pathophysiological functions. 
However, studies of functions of remaining part of protein, des(AngI)AGT is limited. It 
has been reported that des(AngI)AGT inhibited angiogenesis [107, 108]. Lu et al. reported 
that repopulation of des(AngI)AGT in hepatocyte-specific AGT deficient mice increased 
body weight and liver steatosis, but did not affect atherosclerosis, showing that 
des(AngI)AGT exerted an AngII-independent functions [59]. Interestingly, Lu et al. 
aligned the amino acid sequences of AGT from human, rat, mouse and zebrafish, and 
mapped the sequences onto the published structure of AGT [99], and found two highly 
conserved regions, the β-sheet and loop region, on the surface of AGT which are distal to 
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renin-interacting face (Fig. 1.4). These regions may display renin or AngII-independent 
functions. 
 
Figure 1.4 Structural analysis of highly conserved regions in des(AngI)AGT 
 
1.3 Regulation of AGT expression  
AGT production is regulated by many molecules, such as steroid hormones, 
cytokines and AngII [109]. These molecules regulate the activation of transcription factors 
which stimulate AGT transcription and consequently enhance AGT synthesis. There are 
many other factors affecting AGT expression as well, such as nutritional conditions [110], 
sodium concentration [111-113], hypoxia [114], fatty acids [115], insulin [116] and 
hyperglycemia [117]. 
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Glucocorticoid (GC) administration increased AGT expression and production 
[118-121]. Two glucocorticoid response elements (GREs) in 5’-flanking region of AGT 
gene are essential for GC induction [122, 123]. Estrogen is one of steroid hormones 
inducing AGT expression. Estrogen administration increased AGT mRNA level in a 
tissue-specific manner in ovariectomized rats [124]. It has been found that a half-
palindromic estrogen-response element is located on 5’-flanking region of rat AGT gene 
[123], showing a mechanism how estrogen activates AGT transcription. 
In addition, AGT transcription can be induced by cytokines, such as interleukin-lα 
(IL-lα) and tumor necrosis factor (TNF), which is mediated by an acute phase response 
element (APRE) [125-127]. Ron et al. indicated that glucocorticoid is necessary for IL-lα-
induced AGT expression [128]. Lipopolysaccharide (LPS), a bacterial endotoxin 
stimulating host immune defense, induces AGT production [129], which is mediated by 
TNF-a and IL-6 pathways [130, 131], showing important effects of inflammation on AGT 
gene activation.  
Positive feedback regulation of AGT synthesis mediated by AngII, its end product,  
is one of important regulations of AGT production [132]. For examples, 3 days of AngII 
infusion significantly increased plasma AGT concentration in male Sprague-Dawley rats 
with elevated plasma and renal AGT mRNA abundance [133].  
1.4 Tissue and cellular distribution of AGT  
AGT is expressed in many tissues, such as liver, kidney, brain, adipose tissue, aorta 
and heart [119]. Local AGT expression may regulate local tissue functions. AGT is mainly 
produced in hepatocytes in liver [134]. Liver-derived AGT is released to circulation [56, 
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57, 59, 134, 135] and transported to kidney by a megalin-dependent mechanism [135]. 
Deficiency of hepatocyte-derived AGT significantly decreased plasma and renal AGT 
concentration, showing liver is the primary source of AGT production. Moreover, AGT 
has been reported to express in kidney [136] and primarily in S3 segment of renal proximal 
tubules [137-139]. Diet-feeding with different salt levels [112] or plasma glucose 
concentrations [140, 141] regulates renal AGT expression.  Adipose tissues have been 
reported as one of sources of plasma AGT [142-144]. AGT expression in adipose tissues 
[145-147] is associated with development of obesity [148, 149] and affects blood pressure 
[143, 144]. AGT mRNA is also found in whole aorta as well, predominantly in adventitia 
[150, 151]. Tissue-specific AGT expression is associated with regulation of local or 
systemic RAS. 
1.5 Conclusions and perspectives 
Evidence showing the critical roles of AGT in regulation of the RAS and RAS-
related diseases in a tissue-dependent and dose-dependent manners. Although it is known 
that AGT determines the production of angiotensin peptides which affect physiological 
and pathological functions, the studies investigating the functions of whole and cleaved 
AGT in AGT metabolism and consequently angiotensin peptide-associated functions are 
limited. There are still many unknown questions: (1) There are several in vitro studies 
showing the potential effects of amino acids surrounding renin cleavage site on influencing 
renin cleavage of AGT. However, there is no in vivo study to prove the effects of these 
amino acids of AGT on renin activity. Do these amino acids regulate angiotensin peptides 
production and consequently affect its pathophysiological functions in vivo? (2) Highly 
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conserved regions of AGT were reported in our previous publication. The functions of 
these conserved regions remain unclear. Do these highly conserved regions of AGT 
determine its interaction with megalin, an AGT receptor expressing in renal proximal 
tubule? Do these highly conserved regions of AGT influence AngII production and 
atherosclerosis? Therefore, to address these questions, I aim to investigate the roles of 
specific amino acids of AGT in AGT metabolism locally and systemically as well as 
consequently AngII-mediated functions in this study. 
1.6 Specific aims 
To address some of the fundamental questions discussed above, I propose two 
specific aims: 
Aim 1: To investigate the role of two amino acids next to the renin cleavage site of AGT 
in blood pressure and atherosclerosis (Chapter three). 
Aim 2: To determine the effects of highly conserved regions of AGT on blood pressure 
and atherosclerosis. (Chapter four). 
 
Table 1-1 Nonstandard Abbreviations and Acronyms 
Abbreviation  
RAS Renin angiotensin system 
AGT Angiotensinogen 
AngI Angiotensin I 
AngII Angiotensin II 
ACE Angiotensin-converting enzyme 
AT1 receptor Angiotensin II receptor type 1 
hepAGT+/+ mice Hepatocyte-specific AGT+/+ mice 
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hepAGT-/- mice Hepatocyte-specific AGT deficient mice 
siRNAs Small interfering RNAs   
AAV Adeno-associated virus  
Null AAV a null insertion in AAV 
L11V;Y12I Mouse AGT with replacement of the N-terminal 
leucine at position 11 and tyrosine at position 12 to 
valine and isoleucine, respectively 
SPR Surface plasmon resonance 
WT.AAV AAV encoding mouse wild type AGT  
β-sheet.AAV AAV encoding mouse AGT with the β-sheet mutations 
at K253A, H274A, E422A  
W292A.AAV AAV encoding mouse AGT with the loop region 
mutation at W292A  
loop.AAV AAV encoding mouse AGT with the loop region 
mutations at W292A, S298A, V299A 
loop deletion.AAV AAV encoding mouse AGT with the loop region 
mutations at whole conserved sequences which were 
replaced by a GA linker  
β-sheet and loop.AAV AAV encoding mouse AGT with the β-sheet and loop 
region mutations at K253A, H274A, E422A, W292A, 
S298A, and V299A  
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CHAPTER 2. GENERAL METHODS 
This chapter describes the methods, including mouse blood collection, plasma total 
cholesterol measurement, plasma AGT measurement, systolic blood pressure 
measurement, quantification of atherosclerotic lesion sizes and statistical analysis, used in 
studies in Chapter 3 and Chapter 4. 
2.1 Materials 
Reagents used in studies in Chapter 3 and 4 are listed below. 
Table 2-1 Reagents and chemicals used in studies in Chapter 3 and 4. 
Reagents Vendor or Source Catalog # 
Cholesterol E for plasma total 
cholesterol concentrations 
Wako Chemicals USA 999-02601 
Mouse total angiotensinogen (AGT) 
ELISA 
IBL America 27413 
Human total angiotensinogen (AGT) 
ELISA 
IBL America 27412 
Plasma and renal AngII 
concentrations by liquid 
chromatography–mass spectrometry 
Attoquant Diagnostics  
Mouse renin ELISA kit  R&D Systems DY4277 
DuoSet Ancillary Reagent Kit 2  R&D Systems DY008 
Angiotensin II Bachem  H-1705 
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2.2 Plasma profiles 
Mouse blood were collected in the presence of EDTA (final concentration: 1.8 
mg/ml) and a proteinase inhibitor cocktail (provided by Attoquant Diagnostics GmbH, 
Vienna, Austria) to prevent degradation of AGT and angiotensin peptides. During the 
experiment, blood was collected through retro-orbital bleeding at selected intervals. 
Cardiac bleeding via right ventricle was used to collect blood at termination. 
Plasma total cholesterol concentrations were measured using an enzymatic 
commercial kit (Cat # 999-02601; Wako Chemicals USA).  
Plasma AGT concentrations were measured using a mouse AGT ELISA kit (Code 
# 27413; IBL America) or a human AGT ELISA kit (Code # 27412; IBL America). 
Plasma renin concentrations were measured using an ELISA kit (Mouse renin 
ELISA kit, Cat # DY4277; R&D Systems).  
2.3 Systolic blood pressure measurement 
Systolic blood pressure was measured on conscious mice using a non-invasive tail-
cuff system (Coda 8, Kent Scientific Corporation) following our standard protocol [152].  
Data were collected and analyzed based on 20 measurements of each mouse every day for 
3 consecutive days. Mean systolic blood pressure of each mouse from the 3-day 
measurements was used for data analysis. 
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2.4 Quantification of atherosclerosis 
An en face method was used to measure atherosclerotic lesions on the intimal 
surface of the aorta following the recent AHA statement [153], as detailed in our standard 
protocol posted on protocols.io (dx.doi.org/10.17504/protocols.io.bfy8jpzw) and reported 
in our publications (a few examples.[57, 59, 154, 155]). Briefly, the aorta was dissected 
and fixed in 10% neutrally buffered formalin overnight. The adventitial tissues were 
removed, then the intimal surface was exposed by a longitudinal cut and pinned on a black 
wax surface. Images of en face aortas were taken by a Nikon digital camera (Nikon digital 
sight DS-Ri1) with a mm ruler for calibration. Lesions were traced manually in the region 
from the junction of the myocardium (after the aortic root) to 3 mm distal from the left 
subclavian artery using Nikon NIS-Elements software (NIS-Elements AR 5.11.00.) under 
a dissecting microscope. One individual measured the lesion areas, and a senior staff 
member who did not know the animal groups verified the measurements independently.  
Lesion size was presented as percent lesion area as below: 
Percent lesion area (%) =
𝐴𝑡ℎ𝑒𝑟𝑜𝑠𝑐𝑙𝑒𝑟𝑜𝑡𝑖𝑐 𝑙𝑒𝑠𝑖𝑜𝑛 (𝑚𝑚2)
𝐼𝑛𝑡𝑖𝑚𝑎𝑙 𝑎𝑟𝑒𝑎 𝑜𝑓 𝑡ℎ𝑒 𝑎𝑜𝑟𝑡𝑎 (𝑚𝑚2)
× 100 
2.5 Statistical analysis 
Data are represented as means ± standard error of means (SEM). SigmaPlot version 
14.0 (SYSTAT Software Inc.) was used for statistical analyses. To compare multiple-
group data, one-way ANOVA followed by Holm-Sidak method was used for normally 
distributed variables that passed equal variance test. Kruskal-Wallis one-way ANOVA on 
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Ranks followed by Dunn’s method was used for data that did not pass either normality or 
equal variance test. P < 0.05 was considered statistically significant. 
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CHAPTER 3. ROLE OF AMINO ACIDS ADJACENT TO RENIN CLEAVAGE SITE IN 
ANGIOTENSINOGEN IN ANGIOTENSIN II-MEDIATED FUNCTIONS IN MICE 
This chapter is based on our published article titled “The Two Amino Acids 
Proximate to the Renin Cleavage Site in Angiotensinogen Do Not Affect Angiotensin II-
mediated Functions”, with Chia-Hua Wu as the first author (Arterioscler Thromb Vasc 
Biol. 2020 Jul 9;ATVBAHA120314048. doi: 10.1161/ATVBAHA.120.314048.) 
3.1 Abstract 
Renin cleavage of angiotensinogen (AGT) has species specificity. Since the 
residues at positions 11 and 12 are different between human AGT and mouse AGT, we 
determined whether these two residues in AGT affect renin cleavage and angiotensin II-
mediated blood pressure regulation and atherosclerosis using an adeno-associated viral 
(AAV) approach for manipulating AGT in vivo. Hepatocyte-specific AGT deficient 
(hepAGT-/-) mice in an LDL receptor deficient background were infected with AAVs 
containing a null insert, human AGT, or mouse AGT expressing the same residues of the 
human protein at positions 11 and 12 [mouse AGT (L11V;Y12I)]. Expression of human 
AGT in hepAGT-/- mice led to high plasma human AGT concentrations without changes 
in plasma endogenous mouse AGT, plasma renin concentrations, blood pressure, or 
atherosclerosis. This is consistent with human AGT not being cleaved by mouse renin. To 
determine whether the residues at positions 11 and 12 in human AGT lead to the inability 
of mouse renin to cleave human AGT, hepAGT-/- mice were injected with AAV encoding 
mouse AGT (L11V;Y12I). Expression of mouse AGT (L11V;Y12I) resulted in increased 
plasma mouse AGT concentrations, reduced renin concentrations, and increased renal 
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AngII concentrations that were comparable to their concentrations in hepAGT+/+ mice. 
This mouse AGT variant increased blood pressure and atherosclerosis in hepAGT-/- mice 
to the magnitude of hepAGT+/+ mice. In conclusion, replacement of L11 and Y12 to V11 
and I12, respectively, in mouse AGT does not affect renin cleavage, blood pressure, and 
atherosclerosis in LDL receptor deficient mice. 
3.2 Introduction 
Renin cleavage of angiotensinogen (AGT) is the rate-limiting step in producing 
bioactive angiotensin (Ang) peptides [61, 156]. The product of AGT and renin interaction 
is AngI, the first 10 amino acids of the amino terminus of secreted AGT. AngI is highly 
conserved from fly, rodents, to human [61]. One study reported that a conserved disulfide 
bond between Cys18 and Cys138 in human AGT (Cys18 and Cys137 in mouse AGT) 
regulated cleavage of human AGT by human renin in vitro [99]. However, our in vivo 
study demonstrated that this conserved disulfide bond in AGT did not affect AngII 
production and AngII-mediated functions [56], implicating potentially different results 
from in vitro versus in vivo conditions.  
Renin cleavage of AGT displays species specificity [157-159]. For example, human 
AGT is not cleaved by mouse renin, and vice versa as demonstrated in transgenic mouse 
models [158, 159]. Similarly, human AGT is not cleaved by canine renin, but replacement 
of the residues at positions 11 and 12 of human AGT to the two residues in canine AGT 
enhanced its cleavage by canine renin in an in vitro study [105], implicating that these two 
residues adjacent to the renin cleavage site are important for regulating AGT cleavage by 
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renin. However, it has not been determined whether the two amino acids adjacent to the 
AngI sequence in AGT affect renin cleavage and AngII-mediated functions in vivo. 
In this study, we used an adeno-associated viral vector (AAV)-driven expression 
approach to either populate the full length of human AGT or mouse AGT that its two 
residues at positions 11 and 12 were replaced with the two residues in the human protein. 
This approach provided a rapid and efficient manipulation of AGT to study amino acid 
determinants of its interaction with renin in vivo and the consequent AngII-mediated 
physiological and pathophysiological functions such as such as blood pressure and 
atherosclerosis. 
3.3 Methods and materials 
3.3.1 Animals 
Development of hepatocyte-specific AGT deficient mice has been reported 
previously [160-162]. AGT floxed (termed “Agt f/f”) x albumin-Cre-/- (hepAGT+/+) and 
Agt f/f x albumin-Cre+/- (hepAGT-/-) littermates were used for experiments described in this 
manuscript. Genotypes were determined prior to weaning and validated after termination 
by Cre PCR and confirmed by measuring plasma AGT concentrations during the study 
and after termination. Male and female mice in a low-density lipoprotein receptor (LDLR)-
/- background were studied separately following the recent ATVB Council statement [163]. 
All animal experiments reported in this manuscript were performed with the approval of 
the University of Kentucky Institutional Animal Care and Use Committee (IACUC 
protocol number 2006-0009 or 2018-2968). 
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3.3.2 Production and injection of adeno-associated viral (AAV) vector 
AAV vectors (serotype 2/8) driven by a hepatocyte-specific thyroxine-binding 
globulin (TBG) promoter were produced by the Vector Core in the Gene Therapy Program 
at the University of Pennsylvania. Three AAV vectors were made: (1) a null insertion (null 
AAV; used as control), (2) encoding the human AGT (human AGT.AAV), and (3) 
encoding the mouse AGT with L11V;Y12I mutations (L11V;Y12I.AAV). The 
L11V;Y12I represented that the N-terminal leucine at position 11 and tyrosine at position 
12 in mouse AGT were replaced by valine and isoleucine, respectively, to mimic the two 
amino acids at the same positions in human AGT (Figure 3.1A). 
 
Figure 3.1 Experimental designs of AGT mutation and mouse experiment.  
(A) N-terminal amino acids 1 - 10 (AngI) are the same between human and mouse AGT. 
Amino acids at positions 11 and 12 are different between human and mouse AGT. Mouse 
(L11V;Y12I) represent the N-terminal leucine at position 11 and tyrosine at position 12 in 
mouse AGT replaced by valine and isoleucine, respectively, to mimic the two amino acids 
at the same positions of human AGT. (B) Schematic summary of the experimental design: 
LDL receptor -/- mice were injected intraperitoneally with AAVs encoding a null insert, 
human AGT, or mouse AGT (L11V;Y12I). Two weeks after AAV injections, mice were 
fed a Western diet for 12 weeks. Blood pressure was measured on week 10 during the 
Western diet feeding, and atherosclerosis was measured after termination.  
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All mice were fed a normal laboratory diet (Diet # 2918; Envigo), and were injected 
intraperitoneally with AAV vectors (3 x 1010 genome copies/mouse). hepAGT+/+ mice 
were injected with null AAV as a positive control at 8 - 12 weeks of age. Sex- and age-
matched hepAGT-/- mice were randomized to receive AAVs containing a null insert 
(negative control), human AGT, or L11V;Y12I mouse AGT. Two weeks after injection, 
to induce hypercholesterolemia, all study mice have been fed a Western diet (Diet # 
TD.88137; Envigo) for 12 weeks (Figure 3.1B). This diet has high saturated fat, modest 
cholesterol enrichment, and no cholate. The diet contents of this Western diet are shown 
in the Table 3-1. 
Table 3-1 The diet contents of Western diet 
 
 
 
 
 
 
 
  
 
 
3.3.3 Osmotic Mini Pump Implantation and Angiotensin II Infusion 
Saline or angiotensin II (AngII 0.5 µg/kg/min; Cat# H-1706; Bachem) was infused 
subcutaneously via mini osmotic pumps (Alzet Model # 2006; Durect Corp.) as described 
in our publication. 5 Male hepAGT-/- mice were infused with either saline or AngII, and 
their hepAGT+/+ littermates were infused with saline. Mice were sedated with isoflurane 
and pumps were implanted subcutaneously on the right flank of each mouse. Incisions 
were closed with surgical staples and a topical anesthetic cream (LMX4; Ferndale 
Laboratories) was applied immediately after surgery to relieve pain. 
Contents % by weight % kcal 
Protein 17.3 15.2 
Carbohydrate 48.5 42.7 
Fat 21.2 42.0 
Cholesterol 0.2  
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3.3.4 Plasma profiles 
Methods of blood collection, and measurements of plasma total cholesterol and 
plasma AGT were described in Chapter 2 General methods.  
Plasma renin concentrations in male mice were measured using a radioimmunoassy 
method: 5 Mouse plasma samples (8 μl) were incubated in an assay buffer (Na2HPO4 0.1 
M, EDTA 0.02 M, maleate buffer pH 6.5, phenylmethyl-sulfonyl fluoride 2 μl; total 
volume of 250 μl) with an excess of rat AGT at 37 ̊C for 30 min. The reaction was 
terminated by placing samples at 100 ̊C for 5 min. AngI generated in each sample was 
quantified by radioimmunoassay using a commercially available kit (Cat # 1553; 
DiaSorin).  
Plasma renin concentrations in female mice were measured using an ELISA kit 
(Mouse renin ELISA kit, Cat # DY4277; R&D Systems). We compared plasma renin data 
between male and female hepAGT+/+ and -/- mice side-by-side using this ELISA kit as 
shown in Figure 3.2. 
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Figure 3.2 Plasma renin concentrations in hepAGT+/+ and hepAGT-/- male and 
female mice measured using a mouse renin ELISA kit. 
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3.3.5 Systolic blood pressure measurements 
Systolic blood pressure measurement was described in Chapter 2 General methods.  
 
3.3.6 Quantification of atherosclerosis 
An en face method was described in Chapter 2 General methods. 
 
3.3.7 Angiotensin II (AngII) Measurements 
Plasma and renal AngII concentrations were measured using liquid 
chromatography–mass spectrometry by Attoquant Diagnostics GmbH (Vienna, Austria). 
All samples were assayed in a blinded manner. 
 
3.3.8 Statistical analysis 
Statistical analysis was described in Chapter 2 General methods. 
3.4 Results 
3.4.1 Population of human AGT in hepAGT -/- mice did not affect systolic blood 
pressure and atherosclerosis  
In both hepAGT+/+ and -/- male mice infected with null AAV, human AGT was not 
detected in mouse plasma by ELISA. In hepAGT-/- mice infected with AAV encoding 
human AGT, plasma human AGT concentrations were comparable to plasma AGT 
concentrations of humans [164] (Figure 3.3A), but did not affect plasma concentrations of 
endogenous mouse AGT (Figure 3.3B), demonstrating induction of human AGT did not 
affect endogenous mouse AGT concentrations in hepAGT-/- mice. Plasma renin 
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concentrations were comparable between hepAGT-/- mice infected with null AAV and 
human AGT.AAV, both of which were higher than those in hepAGT+/+ mice injected with 
null AAV (Figure 3.3C). Plasma total cholesterol concentrations were above 1,000 mg/dl 
after 12 weeks of Western diet feeding with no differences among the 3 groups (Figure 
3.3D). Since AngII, the major effector peptide of the renin-angiotensin system, regulates 
blood pressure and contributes to development of atherosclerosis, we measured these two 
parameters. Expression of human AGT in hepAGT-/- mice did not change systolic blood 
pressure and atherosclerotic lesion size, when compared to hepAGT-/- mice infected with 
null AAV (Figure 3.3E and F). However, systolic blood pressure and atherosclerotic lesion 
size were much higher in hepAGT+/+ mice than in hepAGT-/- mice injected with either null 
AAV or human AGT AAV. These findings were also confirmed in female mice (Figure 
3.4), demonstrating that human AGT does not affect AngII-mediated functions in mice 
irrespective of sex. 
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Figure 3.3 Human AGT does not affect blood pressure and atherosclerosis in male 
hepAGT-/- mice.  
All study mice were in an LDL receptor-/- background. (A) Plasma human AGT 
concentrations were measured by an ELISA kit that was specific for human AGT. *P<0.05 
versus the other 2 groups by Kruskal–Wallis one-way ANOVA on Ranks with Dunn’s 
method. (B) Plasma mouse AGT concentrations were measured by an ELISA kit that was 
specifically targeting mouse AGT. *P<0.05 versus hepAGT+/+ mice injected with null 
AAV by Kruskal–Wallis one-way ANOVA on Ranks with Dunn’s method. (C) Plasma 
renin concentrations were measured by radioimmunoassay. *P<0.05 versus hepAGT+/+ 
mice injected with null AAV by Kruskal–Wallis one-way ANOVA on Ranks with Dunn’s 
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method. (D) Plasma total cholesterol concentrations were measured by an enzymatic assay 
kit and analyzed with one-way ANOVA. P>0.05.  (E) Systolic blood pressure was 
measured using a tail-cuff system 3 weeks after AAV injection. *P<0.05 versus hepAGT+/+ 
mice injected with null AAV by one-way ANOVA with Holm-Sidak method. (F) 
Atherosclerotic lesion area was quantified by an en face method. *P<0.05 versus 
hepAGT+/+ mice injected with null AAV by one-way ANOVA with Holm-Sidak method. 
N = 16 - 22/group. hepAGT+/+ mice: hepatocyte-specific AGT+/+ mice; hepAGT-/- mice: 
hepatocyte-specific AGT deficient mice. hepAGT+/+ and hepAGT-/- study mice were 
littermates. Mice were 18 - 24 weeks old at termination. 
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Figure 3.4 Human AGT does not change blood pressure and atherosclerosis in 
female hepAGT-/- mice.  
All study mice were in an LDL receptor-/- background. Plasma human (A) and mouse (B) 
AGT concentrations were measured by ELISA. *P<0.05 by Kruskal-Wallis one-way 
ANOVA on Ranks with Dunn’s method. (C) Systolic blood pressure was measured using 
a tail-cuff system. *P<0.05 by one-way ANOVA with Holm-Sidak method. (D) 
Atherosclerotic lesion area was quantified by an en face method. *P<0.05 by one-way 
ANOVA with Holm-Sidak method. N = 5 - 7/group. hepAGT+/+ mice: hepatocyte-specific 
AGT+/+ mice; hepAGT-/- mice: hepatocyte-specific AGT deficient mice. hepAGT+/+ and 
hepAGT-/- study mice were littermates. Mice were 22 – 31 weeks old at termination. 
 
 
3.4.2 Expression of mouse AGT L11V;Y12I in hepAGT-/- mice normalized AngII 
production and blood pressure, and augmented atherosclerosis 
To determine whether N-terminal residues at positions 11 and 12 of AGT affect 
renin cleavage, AAV encoding mouse AGT with the L11V and Y12I substitutions were 
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injected into male hepAGT-/- mice with an LDL receptor-/- background. Administration of 
mouse AGT(L11V;Y12I).AAV led to increased plasma mouse AGT concentrations to be 
comparable as in hepAGT+/+ mice injected with null AAV (Figure 3.5A). Plasma renin 
concentrations were not different between hepAGT+/+ mice and hepAGT-/- mice populated 
with mouse AGT(L11V;Y12I), but lower than hepAGT-/- mice infected with null AAV 
(Figure 3.5B). To confirm that increased plasma renin concentrations in hepAGT-/- were 
due to lower AngII production, we infused either saline or AngII to male hepAGT-/- mice 
and compared with their male hepAGT+/+ littermates infused with saline. Plasma renin 
concentrations were much higher in hepAGT-/- mice infused with saline, compared with 
their wild type littermates. Infusion of AngII in hepAGT-/- mice suppressed plasma renin 
concentrations to the comparable concentrations as in hepAGT+/+ mice (Figure 3.6). 
 
As reported previously [57], plasma AngII concentrations were not different 
between hepAGT+/+ and hepAGT-/- mice, which were also not affected by infection of 
AAVs encoding mouse AGT(L11V;Y12I) (Figure 3.5C). Renal AngII concentrations 
were higher in hepAGT+/+ mice and hepAGT-/- mice infected with mouse 
AGT(L11V;Y12I).AAV than in hepAGT-/- mice infected with null AAV (Figure 3.5D). 
Plasma total cholesterol concentrations were not different among the 3 groups (Figure 
3.5E). Population of mouse AGT(L11V;Y12I) in hepAGT-/- mice led to increased systolic 
blood pressure (Figure 3.5F) and atherosclerotic lesion size (Figure 3.5G), which were 
comparable to the two phenotypes in hepAGT+/+ mice infected with null AAV. A separate 
study demonstrated that female hepAGT-/- mice with an LDL receptor-/- background 
populated with mouse AGT(L11V;Y12I) had comparable blood pressure and 
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atherosclerotic lesion size as female hepAGT+/+ mice injected with null AAV (Figure 3.7), 
while their plasma cholesterol concentrations were not different (Figure 3.8).  
Therefore, the amino-terminal amino acids at positions 11 and 12 of human AGT 
that are adjacent to the renin cleavage site do not determine renal AngII production, blood 
pressure, and atherosclerosis in mice irrespective of sex. 
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Figure 3.5 Mouse AGT(L11V;Y12I) increases blood pressure and augmented 
atherosclerosis in male hepAGT-/- mice.  
All study mice were in an LDL receptor-/- background. (A) Plasma mouse AGT 
concentrations were measured by ELISA. *P<0.05 versus the other 2 groups by Kruskal–
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Wallis one-way ANOVA on Ranks with Dunn’s method. (B) Plasma renin concentrations 
were measured by radioimmunoassay. *P<0.05 versus the other 2 groups by Kruskal–
Wallis one-way ANOVA on Ranks with Dunn’s method. AngII concentrations in plasma 
(C) and kidney (D) were measured using LC-MS/MS. *P<0.05 by Kruskal–Wallis one-
way ANOVA on Ranks with Dunn’s method. (E) Plasma total cholesterol concentrations 
were measured using an enzymatic kit and analyzed by one-way ANOVA. (F) Systolic 
blood pressure was measured using a tail-cuff system. *P<0.05 versus the other 2 groups 
by one-way ANOVA with Holm-Sidak method. (G) Atherosclerotic lesion area was 
quantified by en face method. *P<0.05 versus the other 2 groups by one-way ANOVA with 
Holm-Sidak method. N = 10 - 13/group. hepAGT+/+ mice: hepatocyte-specific AGT+/+ 
mice; hepAGT-/- mice: hepatocyte-specific AGT deficient mice. hepAGT+/+ and hepAGT-
/- study mice were littermates. Mice were 18 – 26 weeks old at termination. 
 
Figure 3.6 Infusion of AngII suppresses plasma renin concentrations in male 
hepAGT-/- mice.  
All study mice were in an LDL receptor-/- background. Plasma renin concentrations were 
measured by ELISA. *P<0.05 by Kruskal-Wallis one-way ANOVA with Dunn's Method. 
N = 6 - 7/group. hepAGT+/+ mice: hepatocyte-specific AGT+/+ mice; hepAGT-/- mice: 
hepatocyte-specific AGT deficient mice. hepAGT+/+ and hepAGT-/- study mice were 
littermates. Mice were 20 – 24 weeks old at termination. 
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Figure 3.7 Mouse AGT(L11V;Y12I) increases blood pressure and augmented 
atherosclerosis in female hepAGT-/- mice.  
All study mice were in an LDL receptor-/- background. (A) Plasma mouse AGT 
concentrations were measured by ELISA. *P<0.05 by Kruskal-Wallis one-way ANOVA 
on Ranks with Dunn’s method. (B) Plasma renin concentrations were measured by ELISA. 
*P<0.001 by one-way ANOVA with Holm-Sidak method. (C) Systolic blood pressure was 
measured using a tail-cuff system. *P<0.05 by one-way ANOVA with Holm-Sidak 
method. (D) Atherosclerotic lesion area was quantified by an en face method. *P<0.05 by 
one-way ANOVA with Holm-Sidak method. N = 5 - 11/group. hepAGT+/+ mice: 
hepatocyte-specific AGT+/+ mice; hepAGT-/- mice: hepatocyte-specific AGT deficient 
mice. hepAGT+/+ and hepAGT-/- study mice were littermates. Mice were 22 – 31 weeks old 
at termination. 
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Figure 3.8 Mouse AGT(L11V;Y12I) does not change plasma cholesterol 
concentrations in female hepAGT-/- mice.  
All study mice were in an LDL receptor-/- background. Plasma total cholesterol 
concentrations were measured using an enzymatic kit and analyzed by one-way ANOVA. 
N = 5 - 11/group. hepAGT+/+ mice: hepatocyte-specific AGT+/+ mice; hepAGT-/- mice: 
hepatocyte-specific AGT deficient mice. hepAGT+/+ and hepAGT-/- study mice were 
littermates. Mice were 22 – 31 weeks old at termination. 
 
3.5 Discussion 
Using an AAV approach for manipulating AGT in hepatocytes, this study reports 
two novel findings. First, human AGT does not affect AngII-mediated blood pressure 
regulation and atherosclerosis in LDL receptor-/- mice lacking endogenous AGT in 
hepatocytes. Second, replacement of the amino-terminal amino acids at positions 11 and 
12 of mouse AGT to mimic human AGT does not impair renin cleavage of AGT, resulting 
in normal renal AngII production and AngII-mediated blood pressure regulation and 
atherosclerosis. 
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Previous studies using human AGT transgenic mice have demonstrated that the 
presence of human AGT in mice does not affect systolic blood pressure [165-167]. In 
human AGT transgenic mice, human AGT was expressed in mice with normal 
concentrations of endogenous mouse AGT and relatively low mouse renin concentrations, 
which does not rule out the possibility that lack of cleavage of human AGT is due to low 
mouse renin concentrations. Our mouse model has several advantages: (1) We used a 
mouse model having low endogenous mouse AGT concentrations but high mouse renin 
concentrations. The low plasma concentrations of mouse AGT were sufficient to enable 
normal growth and kidney development, but led to much lower blood pressure, compared 
to their wild type littermates [56, 57, 59]. Therefore, this mouse model is relevant to 
physiological regulation of the renin-angiotensin system. More importantly, our mouse 
model can address the caveats raised above in previous studies. (2) Our mouse model was 
on an LDL receptor-/- background, so we were able to study two different AngII-induced 
physiologic and pathophysiologic functions, namely blood pressure and atherosclerosis. 
(3) The AAV vector encoding human AGT with a hepatocyte-specific promoter led to 
human AGT produced in hepatocytes, mimicking the normal processing of AGT 
production in liver and secretion to the circulation [57, 135]. 
 
In hepAGT-/- mice infected with AAV containing human AGT, plasma human AGT 
concentrations were above 10 μg/ml, which were 3 - 4-fold higher than plasma endogenous 
mouse AGT concentrations in wild type mice. Although mouse plasma renin 
concentrations were greatly elevated in hepAGT-/- mice compared with wild type mice due 
to removal of AngII-mediated negative feedback, the presence of human AGT did not 
correct plasma renin concentrations, elevate blood pressure, or contribute to the 
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development of atherosclerosis. Therefore, expression of human AGT did not restore 
AngII-mediated functions in hepAGT-/- mice, which supports the notion that human AGT 
is not cleaved by mouse renin in vivo [157-159, 165]. These results confirm previous 
findings of species specificity of AGT and renin interaction [157, 158, 168], and extend 
these findings to the in vivo physiological and pathophysiological setting. 
 
In contrast to population of human AGT in hepAGT-/- mice, population of mouse 
AGT with L11 and Y12 being substituted to the residues of human AGT reduced plasma 
renin concentrations and increased renal AngII concentrations to those of wild type mice. 
As anticipated with these findings, the responses of blood pressure and atherosclerotic 
lesion size were restored in hepAGT-/- mice infected with murine AGT containing these 
two residues of human AGT. These findings provide compelling evidence that the two 
amino acid substitutions between murine and human do not affect renin cleavage of AGT 
and the subsequent AngII-mediated blood pressure regulation and atherosclerosis in 
hepAGT-/- mice. Our results do not support a role for these two residues of human AGT 
as determinants of the species-specificity of the reaction between AGT and renin. 
 
Consistent with our previous report [57], plasma AngII concentrations were not 
different between hepAGT+/+ and -/- mice, irrespective of infection with AAV containing 
a null insert or mutated AGT. In contrast, population of mouse AGT with L11V;Y12I 
substitutions increased renal AngII concentrations to levels of hepAGT+/+ mice, consistent 
with changes of blood pressure and atherosclerosis in these mice. In this study, AngII 
concentrations in kidney were considerably higher than in plasma. AT1a receptor is 
abundant in kidney [169]. Indeed, previous studies have reported that expression of AT1a 
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receptor in kidney, but not in the vasculature, contributes to blood pressure regulation by 
AngII [170, 171]. Since renal AngII, but not plasma AngII, reflects AngII effects on blood 
pressure regulation and atherosclerosis, these results suggest that local tissue AngII (e.g. 
renal) is important in these effects of the renin-angiotensin system. 
 
Plasma AGT concentrations in male hepAGT-/- mice injected AAV encoding 
mouse AGT(L11V;Y12I) were compared to those in their hepAGT+/+ littermates. We 
noted much lower plasma AGT concentrations in female hepAGT-/- mice injected AAV 
encoding mouse AGT(L11V;Y12I) than in their hepAGT+/+ littermates. This sex 
difference has also been reported in mice injected with AAV encoding PCSK9 [172, 173]. 
The mechanism responsible for this sex difference is unclear. Despite the lower plasma 
AGT concentrations in female mice, mouse AGT(L11V;Y12I), but not human AGT, 
increased both blood pressure and atherosclerosis in female hepAGT-/- mice to those of 
their wild type littermates. These results support that the amino-terminal amino acids at 
positions 11 and 12 of human AGT that are adjacent to the renin cleavage site do not 
determine renal AngII production, blood pressure, and atherosclerosis in mice independent 
of sex. 
 
Infusion of AngII in hepAGT-/- mice suppressed plasma renin concentrations, 
supporting that lower blood pressure and atherosclerosis in hepatocyte-specific deletion of 
AGT are attributed to lower AngII concentrations. In future studies, we will determine 
whether blockade of AT1 receptors would inhibit the increased blood pressure and 
atherosclerosis in hepAGT-/- mice injected with AAVs encoding mouse AGT 
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(L11V,Y12I), which would further support that AngII and AT1 receptor interaction is the 
mechanism to blood pressure regulation and atherosclerosis in these mice. 
 
Given the species-specificity of AGT cleavage by renin, we hypothesize that 
differences of either other amino acid sequences or the tertiary protein structure of AGT 
affect the renin cleavage. We therefore aligned AGT protein sequences from different 
species and mapped highly conserved regions of surface residues onto the structure of the 
AGT:renin complex that was published by Zhou et al. [99]. One conserved region of AGT 
is anticipated to be in direct contact with renin and therefore expected to influence species 
specific interaction between AGT and renin. Future studies will aim to manipulate non-
conserved residues in this renin-interacting region to determine whether certain amino acid 
sequences in this region affect the tertiary protein structure or interaction with renin. 
 
 
 
CHAPTER 4. ROLES OF CONSERVED SEQUENCES IN THE Β-SHEET AND LOOP REGIONS OF 
ANGIOTENSINOGEN IN ANGIOTENSIN II-MEDIATED FUNCTIONS IN MICE  
This chapter is based on a manuscript in preparation, titled “Conserved sequences 
in the β-sheet and loop regions of angiotensinogen synergistically regulate plasma 
angiotensinogen production and affect angiotensin II-mediated functions”, with Chia-Hua 
Wu as the first author. Figures based on experiments conducted by others are listed here: 
figure 4.1A was made by Dr. Craig Vander Kooi and data of figure 4.1B was provided by 
Dr. Dudley Strickland.  
4.1  Abstract 
Angiotensinogen (AGT) is the only precursor of all angiotensin peptides. Our 
previous publication shows that two highly conserved regions, the β-sheet and loop region 
on the face of AGT distal to renin interacting face might have renin-independent functions.  
In this study, we determined whether these highly conserved regions in AGT affect 
angiotensin II-mediated blood pressure regulation and atherosclerosis using an adeno-
associated viral (AAV) approach for manipulating AGT in vivo. Surface plasmon 
resonance analysis showed that mutation of W292 in AGT loop region decreased its 
binding affinity to megalin, a protein that is abundant in renal proximal convoluted tubules. 
To determine whether mutation of W292A affected AngII-mediated functions in mice, we 
used hepatocyte-specific AGT deficient (hepAGT-/-) mice in an LDL receptor deficient 
background were infected with AAVs containing a null insert, WT AGT, or mouse AGT 
with W292A mutation. Repopulation of this mutated AGT increased plasma AGT 
concentrations, blood pressure, and atherosclerosis, to the magnitudes, which were 
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comparable to those in hepAGT+/+ mice. Subsequently, to determine whether triple 
nucleotide mutations in the β-sheet or the loop region of AGT affect AngII-mediated 
functions. Infection of AAVs encoding mutations K253A;H274A;E422A of the β-sheet 
region or W297A;S303A;V304A of the loop region in hepAGT-/- mice increased plasma 
AGT concentrations, blood pressure, and atherosclerosis to be equivalent as in hepAGT+/+ 
mice, supporting that the 3 conserved residues of each region do not affect AGT 
metabolism and AngII-mediated functions. Next, we replaced the residues of 291-301 in 
the loop region with a GA linker, and infected hepAGT-/- mice with AAVs encoding this 
protein. Expression of this mutated AGT moderately increased plasma AGT 
concentrations, but increased blood pressure and atherosclerosis to a level comparable to 
hepAGT+/+ mice. We then determined whether conserved sequences in the β-sheet and 
loop regions would have synergistic effects on AngII-mediated functions. Administration 
of AAV encoding mutated sequences in both the β-sheet region (K253A;H274A;E422A) 
and the loop region (W297A;S303A;V304A) did not increase plasma AGT concentrations, 
blood pressure, or atherosclerosis in hepAGT-/- mice, supporting that the conserved 
sequences of these two regions have synergistic effects on AGT metabolism and function. 
In conclusion, the conserved sequences in the β-sheet and loop regions of AGT 
synergistically regulate AGT protein metabolism and AngII-mediated functions.  
4.2 Introduction 
Angiotensinogen (AGT) is the only precursor of the renin angiotensin system 
(RAS), which plays critical roles in physiological and pathological functions, such as 
regulations of sodium/water homeostasis and blood pressure [1, 2]. AGT is a member of 
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the serine-proteinase inhibitor (serpin) family, but it does not have the enzyme activity 
[174, 175]. Intact mouse AGT without a signal peptide has 453 amino acids. The N-
terminal 10-residues peptide, angiotensin I (Ang I), is cleaved by renin. The remaining 
cleaved AGT protein, termed des(AngI)AGT, has 98% of the parent protein, which 
biological functions remain unclear [61]. 
AGT is a key factor affecting AngII-mediated functions, including blood pressure 
and atherosclerosis [56, 57, 59]. However, Lu et al. reported that repopulation of 
des(AngI)AGT in hepatocyte-specific AGT knockout mice which have deficiency of 
plasma AGT did not regulate AngII-mediated functions, such as blood pressure and 
atherosclerosis. Interestingly, repopulation of des(AngI)AGT increased body weight gain, 
liver weight and liver triglyceride content, showing other biological functions of 
des(AngI)AGT [59].  
Analysis of conservation in AGT shows several potential functional surface regions 
in des(AngI)AGT by comparing the amino acid sequences in human, rat, mouse and 
zebrafish and mapping the sequences onto the protein structure of AGT [59, 99]. The N-
terminal AngI, important for production of other angiotensin peptides, is highly conserved 
in species. There are other three unknown surface conserved regions having observed. 
Interestingly, based on the region interacting with renin, one conserved region directly 
interacts with renin and two other conserved regions, the β-sheet face (K253, H274, and 
E422) and the loop region (residues 291-301) with strictly conserved hydrophobic residues 
W292 and V299 along with S298, on the distal face of AGT [59]. Conserved regions of 
AGT distal to renin-binding region might have renin-independent functions, such as the 
interaction with other proteins, instead of interaction with renin. 
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AGT is primarily synthesized in liver and delivered to kidney [134, 135]. The 
uptake of AGT in kidney is mediated by megalin, a multiligand endocytic receptor 
abundant in renal proximal tubules and regulates the homeostasis of the RAS in the kidney 
[57, 138]. It has been found that renal AngII concentration is associated with the 
development of atherosclerosis [56, 57, 59, 156], showing the important roles of the 
interaction of AGT with megalin in AngII-mediated functions. How the interaction of 
AGT with megalin is regulated is still unclear. We hypothesize that conserved regions of 
AGT distal to renin-binding region determine its interaction with megalin and further 
affect AngII-mediated functions. Therefore, in this study, we made several mutations on 
the β-sheet face and loop region of AGT and repopulated mutated AGT by adeno-
associated virous expression approach in hepatocyte-specific AGT deficient mice to 
investigate the effects of conserved regions of AGT on AGT metabolism and AngII-
mediated functions. 
4.3 Methods and materials 
4.3.1 Surface plasmon resonance (SPR) 
Surface plasmon resonance was performed by Dr. Dudley Strickland at the 
University of Maryland. Briefly, binding of AGT (GenScript) to megalin was assessed 
using a Biacore 3000 optical biosensor system (GE Healthcare Life Sciences). Full length 
megalin was coupled to a Sensor Chip CM5 (BR-1003-99; GE Healthcare Life Sciences). 
Various concentrations of AGT ligand in HBS-P Buffer supplemented with 1 mM Ca2+ 
was flowed over the surface of the megalin-coupled sensor chip at a rate of 20 µL/min at 
25°C. 
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4.3.2 Animals 
Development of hepatocyte-specific AGT deficient mice has been reported 
previously [56, 57, 59]. AGT floxed (termed “Agt f/f”) x albumin-Cre-/- (hepAGT+/+) and 
Agt f/f x albumin-Cre+/- (hepAGT-/-) littermates were used for experiments described in this 
manuscript. Genotypes were determined by Cre PCR and confirmed by measuring plasma 
AGT concentrations. Male and female mice in an LDL receptor-/- background were studied 
separately following the recent ATVB Council statement [163]. All animal experiments 
reported in this manuscript were performed with the approval of the University of 
Kentucky Institutional Animal Care and Use Committee (IACUC protocol number 2006-
0009 or 2018-2968). 
 
4.3.3 Production and injection of adeno-associated viral (AAV) vector 
AAV vectors (serotype 2/8) driven by a hepatocyte-specific thyroxine-binding 
globulin (TBG) promoter were produced by the Vector Core in the Gene Therapy Program 
at the University of Pennsylvania. Seven AAV vectors were made: (1) a null insertion (null 
AAV; used as control), (2) encoding the mouse wild type AGT (WT.AAV), (3) encoding 
the mouse AGT with the β-sheet mutations at K253A, H274A, E422A (β-sheet.AAV), (4) 
encoding the mouse AGT with the loop region mutation at W292A (W292A.AAV), (5) 
encoding the mouse AGT with the loop region mutations at W292A, S298A, V299A 
(loop.AAV), (6) encoding the mouse AGT with the loop region mutations at whole 
conserved sequences which were replaced by a GA linker (loop deletion.AAV), and (7) 
encoding the mouse AGT with the β-sheet and loop region mutations at K253A, H274A, 
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E422A, W292A, S298A, and V299A (β-sheet and loop.AAV) (Fig. 4.1A). The W292A 
represents the replacement of N-terminal tryptophan at position 292 to alanine in mouse 
AGT. The triple mutation in the loop region (W292A;S298A;V299A) represents that 
tryptophan at position 292, serine at position 298 and valine at position 299 were replaced 
by alanine, respectively in mouse AGT. The loop deletion represents that an amino acid 
sequence from tryptophan 292 to valine 299 was replaced by a GA linker, which stabilized 
the protein structure. The triple mutation in the β-sheet (K253A;H274A;E422A) represents 
that lysine at position 253, histidine at position 274 and glutamic acid at 422 were replaced 
by alanine, respectively in mouse AGT. The double mutations in the β-sheet and loop 
region (K253A;H274A;E422A;W292A;S298A;V299A) represent that the combination of 
the triple mutations in the β-sheet and the triple mutations in the loop region in mouse 
AGT. 
All mice were fed a normal laboratory diet (Diet # 2918; Envigo), and were injected 
intraperitoneally with AAV vectors (3 x 1010 genome copies/mouse). hepAGT+/+ mice 
were injected with null AAV as a positive control at 8 - 12 weeks of age. Sex- and age-
matched hepAGT-/- mice were randomized to receive AAVs containing a null insert 
(negative control), WT AGT, mutated mouse AGT with the β-sheet, mutated mouse AGT 
with W292A, mutated mouse AGT with the loop mutation, mutated mouse AGT with loop 
deletion mutation, or mutated mouse AGT with the β-sheet and loop mutations. Two 
weeks after AAV injection, to induce hypercholesterolemia, all study mice have been fed 
a Western diet (Envigo, Diet # TD.88137) for 12 weeks. The diet contents of this Western 
diet are shown in the Table 3-1. 
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4.3.4 Plasma profiles 
Methods of blood collection, and measurements of plasma total cholesterol, plasma 
AGT and plasma renin were described in Chapter 2 General methods. 
 
4.3.5 Systolic blood pressure measurements 
Systolic blood pressure measurement was described in Chapter 2 General methods. 
 
4.3.6 Quantification of atherosclerosis 
An en face method was described in Chapter 2 General methods. 
 
4.3.7 Body composition 
Body composition, including whole body fat mass, lean tissue mass, free water, and 
total body water, was measured on conscious mice with EchoMRI-100™ (Echo Medical 
Systems, Houston, TX, USA). 
 
4.3.8 RNA isolation and quantitative PCR 
Total RNA in liver was extracted with a commercial kit (Cat # AS1280;Promega) 
configured with an automated Maxwell 16 purification system (Promega). To quantitate 
mRNA abundance, total RNA was reversely transcribed with an iScript™ cDNA 
Synthesis Kit (Cat #170-8891; Bio-Rad, Hercules, CA, USA), and quantitative PCR 
(qPCR) was performed to quantify mRNA abundance using an SsoFast™ EvaGreen® 
Supermix kit (Cat # 172-5204; Bio-Rad) on a Bio-Rad CFX96 cycler. Data were analyzed 
using ∆∆Ct method and normalized by a geometric mean of internal controls including α-
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actin, GAPDH and RPLP2. Primers used for AGT are 5’-CTGACCCAGTTCTTGCCAC 
and 5’-AACCTCTCATCGTTCCTTGG. 
 
4.3.9 Statistical analysis 
Statistical analysis was described in Chapter 2 General methods. 
4.4 Results 
4.4.1 The loop region of AGT might determine the interaction with megalin 
The interaction of AGT and megalin predisposes to atherosclerosis [57]. To 
investigate whether the loop region of AGT determines the interaction with megalin, we 
analyzed the protein-protein interaction by surface plasmon resonance (SPR). A single 
nucleotide mutation W292A on the loop region of AGT decreased the binding affinity of 
AGT to megalin (Fig. 4.1B), suggesting that the loop region of AGT affects its binding to 
megalin. 
57 
 
 
 
Figure 4.1 Single nucleotide mutation on the loop region (W292A) decreases the 
binding affinity of AGT to megalin.  
(A) Structural analysis of highly conserved regions in des(Ang I) AGT based on 
bioinformatic analyses of AGT gene sequences from human, rat, mouse, and zebrafish. 
Four highly conserved surface regions (Core, renin interacting, βsheet face, and loop) were 
identified in des(AngI) AGT domain. (B) Protein-protein interactions between AGT and 
megalin analyzed by SPR. 
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4.4.2 W292 in the loop region does not affect AGT metabolism and AngII-mediated 
functions. 
Then, we determined whether W292A mutation in the loop region of AGT affects 
AngII-mediated functions. Expression of AGT with W292A (Fig. 4.2A) significantly 
increased plasma AGT concentration in hepAGT-/- mice (Fig. 4.2B), showing that W292A 
of AGT does not affect AGT expression and synthesis. Plasma renin concentration acts as 
an indirect indicator of plasma AngII concentration because of negative feedback 
regulation of AngII production. HepAGT-/- mice repopulated with W292 AGT 
significantly decreased plasma renin concentration which level was comparable with 
hepAGT+/+ mice injected with null AAV and hepAGT-/- infected with WT.AAV (Fig. 
4.2C). Mice body weights were measured weekly to monitor their general health. 
HepAGT-/- mice have less body weight and fat mass gains during 12-weeks western diet 
feeding (Fig. 4.3 A and B), which is consistent to our previous findings [59]. HepAGT-/- 
infected with W292A AGT did not show significant difference in weekly body weight and 
fat mass gains compared to hepAGT+/+ mice injected with null AAV and hepAGT-/- 
injected with WT.AAV (Fig. 4.3A and B). There was no significant difference in plasma 
total cholesterol concentrations among groups (Fig. 4.3C). Since blood pressure and 
development of atherosclerosis are regulated by AngII, the major bioactive peptide of the 
classical renin-angiotensin system, we measured these two parameters to investigate 
whether mutated AGT affects blood pressure and atherosclerosis. HepAGT-/- mice 
expressing W292A AGT displayed significantly higher systolic blood pressure and 
atherosclerotic lesion size than those in hepAGT-/- mice injected with null AAV. 
Moreover, hepAGT-/- mice infected with this mutated AGT did not show significantly 
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change in systolic blood pressure and atherosclerotic lesion size, compared to hepAGT+/+ 
mice infected with null AAV and hepAGT-/- mice infected with WT.AAV (Fig. 4.2D and 
E), demonstrating that AGT with W292A mutation does not affect AngII-mediated 
functions in mice. 
 
Figure 4.2 Single nucleotide mutation (W292) on the loop region does not affect 
AngII-mediated functions in male hepAGT-/- mice.  
All study mice were in an LDL receptor-/- background. (A) Nucleotide mutation on the loop 
region (B) Plasma mouse AGT concentrations were measured by a mouse AGT ELISA kit. 
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*P<0.05 by Kruskal–Wallis one-way ANOVA on Ranks with Dunn’s method. (C) Plasma 
renin concentrations were measured by radioimmunoassay. *P<0.05 by Kruskal-Wallis 
one-way ANOVA on Ranks with Dunn’s method. (D) Systolic blood pressure was 
measured using a tail-cuff system 9 weeks after AAV injection. *P<0.05 by one-way 
ANOVA with Holm-Sidak method. (E) Atherosclerotic lesion area was quantified by an 
en face method. *P<0.05 by one-way ANOVA with Holm-Sidak method. N = 5 - 8/group. 
hepAGT+/+ mice: hepatocyte-specific AGT+/+ mice; hepAGT-/- mice: hepatocyte-specific 
AGT deficient mice. hepAGT+/+ and hepAGT-/- study mice were littermates. Mice were 22 
– 31 weeks old at termination. Mice were 22 – 28 weeks old at termination. 
 
 
Figure 4.3 W292A on the loop region in AGT does not affect body weight, lean and 
fat mass  as well as plasma total cholesterol in male hepAGT-/- mice. 
All study mice were in an LDL receptor-/- background. (A) Weekly body weights in 16 
weeks. (B) Lean mass and fat mass gains after 12 weeks western diet feeding. (C) Plasma 
total cholesterol concentrations were measured by an enzymatic assay kit and analyzed 
with one-way ANOVA. P>0.05. N = 5 - 8/group. hepAGT+/+ mice: hepatocyte-specific 
AGT+/+ mice; hepAGT-/- mice: hepatocyte-specific AGT deficient mice. hepAGT+/+ and 
hepAGT-/- study mice were littermates. Mice were 22 – 28 weeks old at termination. 
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4.4.3 Three nucleotides in the β-sheet and loop regions, respectively, do not affect AGT 
metabolism and AngII-mediated functions. 
In hepAGT-/- mice infected with AAV encoding mutated AGT with triple 
nucleotide mutations (K253A;H274A;E422A) on the β-sheet region (Fig. 4.4A), plasma 
AGT concentrations were comparable to plasma AGT concentrations in hepAGT+/+ mice 
infected with null AAV and hepAGT-/- infected with WT AGT.AAV (Fig. 4.4B), 
demonstrating that triple nucleotide mutations on the β-sheet did not affect AGT 
production. Plasma renin concentrations were comparable between hepAGT-/- mice 
infected with β-sheet.AAV and hepAGT+/+ mice injected with null AAV, both of which 
were lower than those in hepAGT-/- mice injected with null AAV (Fig. 4.4C). Repopulation 
of mutated AGT with the β-sheet mutation did not affect weekly body weight and fat mass 
gains, compared to hepAGT+/+ mice injected with null AAV and hepAGT-/- mice infected 
with WT.AAV (Fig. 4.5A and B). There was no significant difference in plasma total 
cholesterol concentrations among groups (Fig. 4.5C). Expression of AGT with the β-sheet 
mutation in hepAGT-/- mice had increased systolic blood pressure and atherosclerotic 
lesion sizes which were comparable to hepAGT+/+ mice infected with null AAV and 
hepAGT-/- mice infected with WT.AAV (Fig. 4.4D and E), demonstrating that AGT with 
the β-sheet mutation does not affect AngII-mediated functions in mice.  
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Figure 4.4 Triple nucleotide mutations on the β-sheet in AGT do not affect AngII-
mediated functions in male hepAGT-/- mice. 
All study mice were in an LDL receptor-/- background. (A) Nucleotide mutations on the β-
sheet (B) Plasma mouse AGT concentrations were measured by a mouse AGT ELISA kit. 
*P<0.05 by one-way ANOVA with Holm-Sidak method. (C) Plasma renin concentrations 
were measured by radioimmunoassay. *P<0.05 by Kruskal-Wallis one-way ANOVA on 
Ranks with Dunn’s method. (D) Systolic blood pressure was measured using a tail-cuff 
system 9 weeks after AAV injection. *P<0.05 by one-way ANOVA with Holm-Sidak 
method. (E) Atherosclerotic lesion area was quantified by an en face method. *P<0.05 by 
one-way ANOVA with Holm-Sidak method. N = 3 - 6/group. hepAGT+/+ mice: 
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hepatocyte-specific AGT+/+ mice; hepAGT-/- mice: hepatocyte-specific AGT deficient 
mice. hepAGT+/+ and hepAGT-/- study mice were littermates. Mice were 18 – 32 weeks old 
at termination. 
 
 
 
Figure 4.5 Triple nucleotide mutations on the β-sheet in AGT do not affect body 
weight, plasma total cholesterol as well as lean and fat mass in male hepAGT-/- mice. 
All study mice were in an LDL receptor -/- background. (A) Weekly body weights in 12 
weeks. (B) Lean mass and fat mass gains after 12 weeks western diet feeding. (C) Plasma 
total cholesterol concentrations were measured by an enzymatic assay kit and analyzed 
with one-way ANOVA. P>0.05. N = 3 - 6/group. hepAGT+/+ mice: hepatocyte-specific 
AGT+/+ mice; hepAGT-/- mice: hepatocyte-specific AGT deficient mice. hepAGT+/+ and 
hepAGT-/- study mice were littermates. Mice were 18 – 32 weeks old at termination. 
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We investigated whether three nucleotide mutations in the loop region (W292A, 
S298A, V299A) of AGT (Fig. 4.6A) affect AGT production and AngII-mediated 
functions.  Expression of AGT with triple nucleotide mutations on the loop region did not 
significantly change plasma AGT concentrations, compared to plasma AGT 
concentrations in hepAGT+/+ mice infected with null AAV and hepAGT-/- infected with 
WT AGT.AAV (Fig. 4.6B). Plasma renin concentrations were comparable between 
hepAGT-/- mice infected with loop.AAV, hepAGT-/- mice infected with WT AGT.AAV 
and hepAGT+/+ mice, all of which were lower than those in hepAGT-/- mice injected with 
null AAV (Fig. 4.6C). HepAGT-/- mice infected with this mutated AGT did not show 
significant difference in body weight and fat mass gains compared to WT controls (Fig. 
4.7A and B). Also, plasma total cholesterol concentrations of hepAGT-/- mice infected with 
loop.AAV were not significantly different from WT controls, although they were higher 
than those in hepAGT-/- injected with null AAV (Fig. 4.7C). Repopulation of this mutated 
AGT did not significantly change systolic blood pressure and atherosclerosis, compared 
to hepAGT+/+ mice infected with null AAV and hepAGT-/- infected with WT AGT.AAV 
(Fig. 4.6D and E). Taken together, three residues in the β-sheet and loop region, 
respectively, are not critical for AGT metabolism and consequently AngII-mediated 
functions. 
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Figure 4.6 Triple nucleotide mutations on the loop region in AGT do not affect 
AngII-mediated functions in male hepAGT-/- mice. 
All study mice were in an LDL receptor-/- background. (A) Nucleotide mutations on the 
loop region (B) Plasma mouse AGT concentrations were measured by a mouse AGT 
ELISA kit. *P<0.05 by one-way ANOVA with Holm-Sidak method. (C) Plasma renin 
concentrations were measured by radioimmunoassay. *P<0.05 by Kruskal-Wallis one-way 
ANOVA on Ranks with Dunn’s method. (D) Systolic blood pressure was measured using 
a tail-cuff system 9 weeks after AAV injection. *P<0.05 by one-way ANOVA with Holm-
Sidak method. (E) Atherosclerotic lesion area was quantified by an en face method. 
*P<0.05 by one-way ANOVA with Holm-Sidak method. N = 7 - 10/group. hepAGT+/+ 
66 
 
mice: hepatocyte-specific AGT+/+ mice; hepAGT-/- mice: hepatocyte-specific AGT 
deficient mice. hepAGT+/+ and hepAGT-/- study mice were littermates. Mice were 20 – 34 
weeks old at termination. 
 
 
 
Figure 4.7 Triple nucleotide mutations on the loop region do not affect body weight, 
plasma total cholesterol as well as lean and fat mass in male hepAGT-/- mice. 
All study mice were in an LDL receptor-/- background. (A) Weekly body weights in 12 
weeks. (B) Lean mass and fat mass gains after 12 weeks western diet feeding. *P<0.05 by 
one-way ANOVA with Holm-Sidak method. (C) Plasma total cholesterol concentrations 
were measured by an enzymatic assay kit. *P<0.05 by one-way ANOVA with Holm-Sidak 
method. N = 7 - 10/group. hepAGT+/+ mice: hepatocyte-specific AGT+/+ mice; hepAGT-/- 
mice: hepatocyte-specific AGT deficient mice. hepAGT+/+ and hepAGT-/- study mice were 
littermates. Mice were 20 – 34 weeks old at termination. 
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4.4.4 Expression of mutated AGT with loop deletion in hepAGT-/- mice moderately 
affects AGT production but does not affect AngII-mediated functions. 
We then investigated whether replacement of the residues of 291-301 in the loop 
region with a GA linker (Fig. 4.8A) affects AGT metabolism and AnII-mediated functions 
in hepAGT-/- mice infected with loop deletion.AAV. HepAGT-/- mice infected with 
loop.deletion AAV moderately increased plasma AGT concentrations, compared to 
hepAGT+/+ mice injected with null AAV (Fig. 4.8B), showing that the whole conserved 
sequence replacement in the loop region moderately affects AGT production. Liver mRNA 
abundance of AGT in hepAGT-/- infected with loop deletion.AAV was not significantly 
different from hepAGT+/+ mice injected with null AAV (Fig. 4.9A), suggesting that this 
mutation does not affect expression of AGT. In hepAGT-/- mice infected with AAVs 
encoding this protein, plasma renin concentration (131.4 ± 18.1 ng/ml) significantly 
increased compared to hepAGT+/+ injected with null AAV (39.3 ± 3.7 ng/ml) (Fig. 4.8C).  
Although there was no significant difference in plasma renin concentration between 
hepAGT-/- mice infected with loop deletion.AAV and hepAGT-/- mice injected with null 
AAV (482.9 ± 154.9 ng/ml), plasma renin concentrations of hepAGT-/- mice infected with 
loop deletion.AAV were about 3.5 times lower than plasma renin concentrations of 
hepAGT-/- mice injected with null AAV (Fig. 4.8C), suggesting that systemic AngII 
concentrations were higher in hepAGT-/- mice infected with loop deletion.AAV than in 
hepAGT-/- mice injected with null AAV. HepAGT-/- mice infected with this mutated AGT 
did not show significant difference in body weight and fat mass gains compared to WT 
controls (Fig. 4.9B and C). Plasma total cholesterol concentrations were not significantly 
different among groups (Fig. 4.9D). For AngII-mediated functions, expression of AGT 
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with the loop deletion mutation still significantly increased systolic blood pressure and 
atherosclerosis compared to hepAGT+/+ mice injected with null AAV (Fig. 4.8D and E). 
A separate female mice study demonstrated that female hepAGT-/- mice with an LDL 
receptor-/- background populated with mutated AGT with loop deletion had comparable 
blood pressure and atherosclerotic lesion size as female hepAGT+/+ mice injected with null 
AAV, while their body weight and fat mass gains did not change (Fig. 4.10). In summary, 
replacement of the whole conserved sequences of the loop region with a GA linker does 
not affect blood pressure and atherosclerosis. 
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Figure 4.8 GA linker substitution on the loop region in AGT decreases plasma AGT 
concentration but did not affect AngII-mediated functions in male hepAGT-/- mice. 
All study mice were in an LDL receptor-/- background. (A) Nucleotide mutation on the loop 
region (B) Plasma mouse AGT concentrations were measured by a mouse AGT ELISA kit. 
*P<0.05 by Kruskal–Wallis one-way ANOVA on Ranks with Dunn’s method. (C) Plasma 
renin concentrations were measured by radioimmunoassay. *P<0.05 by Kruskal-Wallis 
one-way ANOVA on Ranks with Dunn’s method. (D) Systolic blood pressure was 
measured using a tail-cuff system 9 weeks after AAV injection. *P<0.05 by one-way 
ANOVA with Holm-Sidak method. (E) Atherosclerotic lesion area was quantified by an 
en face method. *P<0.05 by one-way ANOVA with Holm-Sidak method. N = 6 - 7/group. 
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hepAGT+/+ mice: hepatocyte-specific AGT+/+ mice; hepAGT-/- mice: hepatocyte-specific 
AGT deficient mice. hepAGT+/+ and hepAGT-/- study mice were littermates. Mice were 18 
– 20 weeks old at termination. 
 
 
 
Figure 4.9 GA linker substitution on the loop region in AGT does not affect mRNA 
abundance, body weight, lean and fat mass  as well as plasma total cholesterol in 
male hepAGT-/- mice. 
All study mice were in an LDL receptor-/- background. (A) mRNA abundance of liver 
AGT. *P<0.05 by Kruskal–Wallis one-way ANOVA on Ranks with Dunn’s method. (B) 
Weekly body weights in 12 weeks. (C) Lean mass and fat mass gains after 12 weeks 
western diet feeding. *P<0.05 by one-way ANOVA with Holm-Sidak method. (D) Plasma 
total cholesterol concentrations were measured by an enzymatic assay kit and analyzed 
with one-way ANOVA. P>0.05. N = 6 - 7/group. hepAGT+/+ mice: hepatocyte-specific 
AGT+/+ mice; hepAGT-/- mice: hepatocyte-specific AGT deficient mice. hepAGT+/+ and 
hepAGT-/- study mice were littermates. Mice were 18 – 20 weeks old at termination. 
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Figure 4.10 GA linker substitution on the loop region in AGT did not affect growth 
and AngII-mediated functions in female hepAGT-/- mice.  
All study mice were in an LDL receptor-/- background. (A) Weekly body weights in 12 
weeks. (B) Lean mass and fat mass gains after 12 weeks western diet feeding. *P<0.05 by 
Kruskal-Wallis one-way ANOVA on Ranks with Dunn’s method. (C) Plasma total 
cholesterol concentrations were measured by an enzymatic assay kit and analyzed with 
one-way ANOVA. P>0.05. (D) Systolic blood pressure was measured using a tail-cuff 
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system 9 weeks after AAV injection. *P<0.05 by one-way ANOVA with Holm-Sidak 
method. (E) Atherosclerotic lesion area was quantified by an en face method. *P<0.05 by 
one-way ANOVA with Holm-Sidak method. N = 6 - 10/group. hepAGT+/+ mice: 
hepatocyte-specific AGT+/+ mice; hepAGT-/- mice: hepatocyte-specific AGT deficient 
mice. hepAGT+/+ and hepAGT-/- study mice were littermates. Mice were 18 – 28 weeks old 
at termination. 
 
4.4.5 Repopulation of AGT with mutations on the β-sheet and loop region in hepAGT-/-
mice affects AGT production and AngII-mediated functions. 
We then determined whether conserved sequences in the β-sheet and loop regions 
would have synergistic effects on AngII-mediated functions. Administration of AAV 
encoding mutated sequences in both the β-sheet region (K253A;H274A;E422A) and the 
loop region (W297A;S303A;V304A) (Fig. 4.11A) did not increase plasma AGT 
concentrations, compared to hepAGT-/- mice injected with null AAV (Fig. 4.11B). 
Although mRNA abundance of liver AGT in hepAGT-/- mice infected with β-sheet and 
loop.AAV was significantly lower than hepAGT+/+ mice injected with null AAV, it was 
higher than hepAGT-/- mice injected with null AAV (Fig. 4.12A), suggesting that the β-
sheet and loop region mutation might affect AGT synthesis in liver. Plasma renin 
concentrations of hepAGT-/- mice infected with β-sheet and loop.AAV significantly 
increased compared to WT controls (Fig. 4.11C). Body weight and fat mass gains were 
decreased (Fig. 4.12B and C). Plasma total cholesterol concentrations were not 
significantly different among groups (Fig. 4.12D). Administration of AGT with the β-sheet 
and loop region mutation did not increase systolic blood pressure and atherosclerosis 
compared to hepAGT-/- mice injected with null AAV (Fig. 4.11D and E). A separate 
female mice study demonstrated that female hepAGT-/- mice with an LDL receptor-/- 
background populated with AGT with mutations on the β-sheet and loop region had 
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significantly decreased blood pressure and atherosclerotic lesion size as female hepAGT-
/- mice injected with null AAV, while their body weight and fat mass gains also decreased 
(Fig. 4.13). In summary, the β-sheet and loop region synergistically regulate AGT 
metabolism and then consequently AngII-mediated functions in both male and female 
mice. 
 
74 
 
 
Figure 4.11 Mutations on the β-sheet (K253A, H274A, E422A) and loop region 
(W292A, S298A, V299A) of AGT decrease plasma AGT concentration and affect 
AngII-mediated functions in male hepAGT-/- mice. 
All study mice were in an LDL receptor-/- background. (A) Nucleotide mutations on the β-
sheet and loop region (B) Plasma mouse AGT concentrations were measured by a mouse 
AGT ELISA kit. *P<0.05 by Kruskal–Wallis one-way ANOVA on Ranks with Dunn’s 
method. (C) Plasma renin concentrations were measured by radioimmunoassay. *P<0.05 
by Kruskal-Wallis one-way ANOVA on Ranks with Dunn’s method. (D) Systolic blood 
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pressure was measured using a tail-cuff system 9 weeks after AAV injection. *P<0.05 by 
Kruskal-Wallis one-way ANOVA on Ranks with Dunn’s method. (E) Atherosclerotic 
lesion area was quantified by an en face method. *P<0.05 by one-way ANOVA with Holm-
Sidak method. N = 7 - 10/group. hepAGT+/+ mice: hepatocyte-specific AGT+/+ mice; 
hepAGT-/- mice: hepatocyte-specific AGT deficient mice. hepAGT+/+ and hepAGT-/- study 
mice were littermates. Mice were 18 – 20 weeks old at termination. 
 
 
Figure 4.12 Mutations on the β-sheet (K253A, H274A, E422A) and loop region 
(W292A, S298A, V299A) of AGT do not affect body weight, plasma total cholesterol 
as well as lean and fat mass in male hepAGT-/- mice. 
All study mice were in an LDL receptor-/- background. (A) mRNA abundance of liver 
AGT. *P<0.05 by Kruskal-Wallis one-way ANOVA on Ranks with Dunn’s method.   (B) 
Weekly body weights in 12 weeks. (C) Lean mass and fat mass gains after 12 weeks 
western diet feeding. *P<0.05 by one-way ANOVA with Holm-Sidak method. (D) Plasma 
total cholesterol concentrations were measured by an enzymatic assay kit and analyzed 
with one-way ANOVA. P>0.05. N = 7 - 10/group. hepAGT+/+ mice: hepatocyte-specific 
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AGT+/+ mice; hepAGT-/- mice: hepatocyte-specific AGT deficient mice. hepAGT+/+ and 
hepAGT-/- study mice were littermates. Mice were 18 – 20 weeks old at termination. 
 
 
Figure 4.13 Mutations on the β-sheet (K253A, H274A, E422A) and loop region 
(W292A, S298A, V299A) of AGT decrease plasma AGT concentration and affect 
AngII-mediated functions in female hepAGT-/- mice. 
All study mice were in an LDL receptor-/- background. (A) Plasma mouse AGT 
concentrations were measured by a mouse AGT ELISA kit. *P<0.05 by Kruskal–Wallis 
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one-way ANOVA on Ranks with Dunn’s method. (B) Plasma renin concentrations were 
measured by radioimmunoassay. *P<0.05 by Kruskal-Wallis one-way ANOVA on Ranks 
with Dunn’s method. (C) Weekly body weights in 12 weeks. (D) Lean mass and fat mass 
gains after 12 weeks western diet feeding.  (E) Systolic blood pressure was measured using 
a tail-cuff system 9 weeks after AAV injection. *P<0.05 by Kruskal-Wallis one-way 
ANOVA on Ranks with Dunn’s method. (F) Atherosclerotic lesion area was quantified by 
an en face method. *P<0.05 by one-way ANOVA with Holm-Sidak method. N = 9 - 
11/group. hepAGT+/+ mice: hepatocyte-specific AGT+/+ mice; hepAGT-/- mice: 
hepatocyte-specific AGT deficient mice. hepAGT+/+ and hepAGT-/- study mice were 
littermates. Mice were 19 – 31 weeks old at termination. 
 
4.5 Discussion 
This study reports three novel findings. First, the loop region might determine the 
interaction of AGT with megalin. Secondly, mutation on each β-sheet or loop region of 
AGT does not affect AGT function and AngII-mediated functions. Thirdly, the β-sheet 
and loop region of AGT synergistically regulate AGT synthesis and consequently AngII-
mediated functions. 
The β-sheet and loop region, highly conserved amino acids on the surface of AGT 
which are distal to renin interacting face, were firstly reported in our previous publication 
[59]. Lu et al. reported that these conserved regions in des(AngI)AGT might have 
important roles in the regulation of AGT functions. Moreover, our previous publication 
demonstrates the critical roles of AGT and megalin in renal RAS homeostasis and 
atherosclerosis [57]. Therefore, in this study, firstly, we tested the protein-protein 
interaction of W292A AGT and megalin. We found that the loop region of AGT affected 
its binding to megalin (Fig. 4.1B). However, expression of W292A AGT in hepAGT-/- 
mice did not affect systolic blood pressure and atherosclerosis (Fig. 4.2). We further 
investigated the effects of the β-sheet and loop region on AGT metabolism and AnII-
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mediated functions by several different mutations. Triple nucleotide mutations on the β-
sheet did not affect AGT production and blood pressure as well as atherosclerosis (Fig. 
4.4), indicating that the β-sheet is not critical for regulation of AGT synthesis. However, 
the β-sheet synergistically regulated AGT production and consequently AngII-mediated 
functions with the loop region (Fig. 4.11). Triple nucleotide mutations on the loop region 
did not affect AGT synthesis and AngII-mediated functions (Fig. 4.6). Expression of 
replacement of whole conserved sequence of the loop region with a GA linker in hepAGT-
/- mice showed the reduced plasma AGT concentration without changing blood pressure 
or atherosclerosis, compared to hepAGT+/+ mice injected with null AAV or hepAGT-/- 
mice infected with WT.AAV (Fig. 4.8), implicating that the loop region of AGT is 
involved in the regulation of AGT synthesis. Interestingly, combination of triple 
nucleotide mutations on both β-sheet and loop region showed the most profound effects 
on AGT synthesis and abolished AngII-mediated functions (Fig. 4.11). Studies of 
functions of des(AngI)AGT are limited. Des(AngI)AGT has been reported to inhibit 
angiogenesis [107, 176]. Des(AngI)AGT can form high molecule AGT by RCL(reactive 
center loop)-β-sheet polymerization [177], which is associated with pre-eclampsia [178, 
179]. These studies reveal the other important roles of des(AngI)AGT in 
pathophysiological functions. In this study, we demonstrate that highly conserved 
sequences, the β-sheet and loop region of AGT regulate AGT functions and the loop region 
affect the binding of AGT to megalin. 
Lu et al. demonstrated that des(AngI)AGT, a conserved serpin domain of AGT, 
exert an AngII-independent functions, such as body weight gain, liver weight, and liver 
triglyceride content [59]. How des(AngI)AGT increases body weight gain, liver 
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triglyceride content and liver weight remain unclear. In this study, we observed that 
mutations on these highly conserved sequences did not change fat mass or body weight 
gain compared to WT controls, showing that the β-sheet or the loop region are not essential 
for the regulation of body weight and fat mass gains in mice fed a Western diet.  
It has been shown that leukocytes-specific components of the RAS are not critical 
for atherosclerosis, although leukocytes are involved in the pathogenesis of 
atherosclerosis. For example, deficiency of AGT [59] or AT1 receptor [18] in bone 
marrow-derived cells did not affect atherosclerosis. Moreover, AngII concentration and 
AT1 receptor expression are predominant in kidney, revealing the potential pivotal roles 
of renal RAS in atherosclerosis. AGT and megalin interactions contribute to renal RAS 
homeostasis and atherosclerosis. In this study, we investigated how AGT and megalin 
interaction regulates AngII-mediated functions. However, there are some difficulties 
limiting the explores of interactions of megalin with highly conserved sequences of AGT: 
(1) big size of megalin (about 600 kD)[180, 181] causing the difficulty of purification, and 
(2) low AGT protein production due to mutations. Moreover, since mutation on the β-sheet 
did not change plasma AGT concentration and blood pressure as well as atherosclerosis, 
we only investigated whether the loop region is essential for AGT binding to megalin in 
SPR analysis. The data showed that W292 in the loop region is involved in the interaction 
with megalin. Megalin has four ligand-binding regions [180]. Therefore, future studies 
will aim to study potential interactions of AGT with which ligand-binding domains to 
investigate and explore the potential roles of local RAS in development of atherosclerosis.  
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CHAPTER 5. GENERAL DISCUSSION – LIMITATIONS, SOLUTIONS AND CONTRIBUTIONS OF 
STUDIES REGARDING SPECIFIC DOMAINS OF AGT IN ANGII-MEDIATED FUNCTIONS  
This chapter is an overall discussion based on chapter 3 and 4. This chapter 
discusses the limitations of these studies, the ways to solve problems, future directions, and 
importance and contributions of these studies in cardiovascular diseases. 
5.1  Amino acids adjacent to renin cleavage site (Chapter 3) 
Our results showed that two amino acids at position 11 and 12 adjacent to renin 
cleavage site in mouse AGT do not affect renin cleavage of AGT and consequently AngII-
mediated functions in hepAGT-/- mice. This results support the in vitro finding of Hatae at 
el. [182], but are contrary to the data of Burton et al who demonstrated that the amino acids  
are critical for renin cleavage of AGT by using synthetic tetradecapeptides and human or 
canine renin. These results implicate that amino acid residues next to renin cleavage site 
in different species might have different effects on catalytic activity of renin from different 
species. In addition to amino acids, tertiary protein structure of AGT and specificities of 
renin from different species might also contribute to the efficiency of renin cleavage of 
AGT. 
N-terminal amino acids around renin cleavage sites also regulate the catalytic 
activity of renin. 12' isoleucine replaced by tyrosine residue in human tetradecapeptide 
significantly decreased kcat of renin [104]. Six residues surrounding the renin cleavage site 
of human AGT are important for human renin action [106]. In a preeclamptic patient, there 
was a mutation with the replacement of leucine by phenylalanine at position 10 of AGT 
(L10F), which altered the reaction of AGT with renin [183]. These studies show the other 
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potential amino acids regulating renin activity. Our previous studies reported that there are 
highly conserved regions in AGT, including hydrophobic core, AngI, renin interacting face, 
β-sheet and loop region [59]. Conserved sequence of renin interacting face may determine 
the efficiency of renin cleavage of AGT. Future studies will aim to manipulate conserved 
residues in this renin-interacting region to determine whether certain amino acid sequences 
in this region affect the tertiary protein structure or interaction with renin. 
In addition, plasma L11V;Y12I mouse AGT repopulation showed difference in 
hepAGT-/- male (Fig. 3.5A) and female mice (Fig. 3.7A). Much lower plasma AGT 
concentrations was expressed in female hepAGT-/- mice infected AAV encoding mouse 
AGT(L11V;Y12I) than in their hepAGT+/+ littermates. This sex difference has also been 
reported in mice injected with AAV encoding PCSK9 [172, 173], although the mechanism 
of AAV-mediated protein expression contributing to sex difference is unclear. For mouse 
AGT measurement, we have been using the same ELISA kit for more than 10 years (the 
best kit among 4 commercially available kits we tested) and documented the batch number 
of the ELISA kit in each experiment as a lab routine. Despite the same kit which has been 
used, different batch number and measurements conducted by different persons might get 
the slightly different absolute values of AGT concentrations (Table 5-1). 
Table 5-1 Plasma AGT concentrations in wild type mice measured using different 
batches of the mouse AGT ELISA kit (Code # 27413; IBL America). 
Batch # Date performed Sex Plasma AGT (ng/ml) 
 
1K-226 
 
11/07/2013 
Male 2868 ± 668 
Female 3063 ± 299 
1I-412 02/03/2015 Male 3592 ± 253 
1J-427 10/05/2017 Male 3620 ± 128 
1F-713 03/08/2018 Female 1798 ± 30 
1C-3 09/04/2018 Male 1760 ± 56 
1B-820 05/30/2020 Male 1554 ± 47 
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Systolic blood pressures in hepAGT+/+ mice were about 140-160 mmHg in Human 
AGT AAV study and L11V;Y12I AGT AAV study (Chapter 3) and conserved regions 
AGT studies (Chapter 4) by using a tail-cuff system, CODA high throughput system (Kent 
Scientific). Hypertension is defined as a systolic blood pressure (SBP) ≥130 mmHg and a 
diastolic blood pressure (DBP) ≥80 mmHg in adults [184]. Compared to human, SBP in 
hepAGT+/+ mouse was relatively high. The accuracy of this tail-cuff system is affected by 
many factors, including environment temperature, stress on mice and tail blood volume 
status. (1) Multiple training sessions, (2) taping the distal part of the tail on the platform, 
(3) cover the animal holder to reduce light and noise, and (4) check the temperature of 
platform are helpful to minimize agitation of mice and reduce issues in SBP measurement 
[185, 186]. In contrast, a tail-cuff blood pressure measurement has several advantages. For 
example, measurements in conscious animals are close to physiological conditions. A tail-
cuff system is a simple and rapid way to test blood pressure within multiple animals, 
without anesthesia or invasive surgery. Moreover, in our previous publications, hepAGT+/+ 
mice also had consistent systolic blood pressures [56, 59], suggesting that comparability 
of data in our blood pressure measurement.   
5.2 Highly conserved regions of AGT (Chapter 4) 
Our results showed that highly conserved regions, the β-sheet and loop region of 
AGT synergistically regulate AGT synthesis and consequently AngII-mediated functions, 
which reveals a novel biological function of these highly conserved regions. Moreover, 
the loop region might be one of critical region determining the interaction with megalin.  
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AGT with (1) a single nucleotide mutation on the loop region, (2) triple nucleotide 
mutations on the loop region, (3) triple nucleotide mutations on the β-sheet, or (4) loop 
deletion mutation all did not affect blood pressure and atherosclerosis in hepAGT-/- mice 
fed a Western diet for 12 weeks. The RAS are regulated under different stress conditions, 
such as high salt intake and low salt intake, which associates with hypertension [187-190]. 
Thus, whether expression of AGT mutants exerts different effects on AngII-mediated 
functions in mice fed a high salt diet or low salt diet is another future direction to study the 
functions of conserved regions of AGT in AGT metabolism and AngII-mediated functions 
in mice under stress conditions. 
 Plasma AGT concentration was moderately increased in hepAGT-/- mice infected 
with AAV encoding AGT with loop deletion, and blood pressure and atherosclerosis in 
these mice were significantly increased to a comparable level to hpeAGT+/+ mice infected 
with null AAV. However, hepAGT-/- mice infected with AAV encoding AGT with 
mutation on the β-sheet and loop region failed to repopulate AGT mutant, increase blood 
pressure and atherosclerosis which were all comparable to hepAGT-/- mice infected with 
null AAV. The question here is what the exact concentration of AGT can produce AngII 
which concentration is enough to regulate and affect blood pressure and atherosclerosis. It 
is difficult to define biological functions which are affected by a specific dose of AGT. To 
address this question, hepAGT+/+ mice could be injected with different doses of GalNAc-
conjugated AGT antisense oligonucleotides (ASO) to specifically inhibit AGT expression 
in hepatocytes. Blood pressure and atherosclerosis could be tested in hepAGT+/+ mice 
expressing with different concentrations of AGT. 
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In this study, we only tested the interaction of megalin and AGT with a single 
nucleotide mutation (W292A). There are some difficulties limiting the assessments of the 
binding affinities of other mutated AGT with megalin. Firstly, megalin is about 600-kD 
membrane-bound protein [180, 181], which big size causing the difficulty of purification. 
Secondly, mutations on the β-sheet and loop region at the same time cause the low 
recombinant AGT protein production.  
In the future studies, to solve the problem of purification of megalin, four ligand-
binding domains of megalin can be generated separately or generated with different 
combinations to investigate more detailed interactions between AGT and megalin in vitro. 
In addition to using purified megalin protein, megalin-expressing cells [191, 192] can be 
used to study the interaction of AGT with megalin in cells. Retinoic acids and dibutyrl 
cAMP-treated F9 cells (testicular teratoma stem cell line; ATCC) express megalin (Fig. 
5.1). I used recombinant AGT proteins with flag-tag labeling (generated by GenScript) to 
do AGT uptake experiment in F9 cells to study the interaction of AGT with megalin. 
However, I failed to get consistent results from cell immunofluorescent staining and 
western blotting analysis (Fig. 5.2). There were some issues in this experiment: (1) 
antibody targeting AGT was failed to detect AGT in cells. Also, antibody targeting flag 
tag did not specifically bind to AGT in western blotting analysis, suggesting that AGT 
detected in cell immunofluorescent staining by anti-flag antibody might be a non-specific 
result; (2) how long is enough for AGT uptake into cells is still unclear. Thus, to figure 
out the availability of specific antibodies targeting recombinant AGT protein and the 
optimal AGT incubation time and condition is the first thing to do in the future studies. 
 
85 
 
 
Figure 5.1 Immunofluorescence confocal microscopy of F9 cells.  
F9 cells express megalin after retinoic acids and dibutyrl cAMP incubation for 4 days.  
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Figure 5.2 Recombinant AGT protein uptake experiments in F9 cells.  
F9 cells incubated with retinoic acids and dibutyrl cAMP for 4 days to induce megalin 
expression, and then incubated with 30 nM recombinant AGT for 30 min or 1 h. (A) Fixed 
cells were stained with DAPI, anti-megalin antibody, anti-flag antibody or anti-AGT 
antibody. (B) Cell lysates were used for western blotting analysis. Rabbit anti-flag: IRDye 
800CW (green color). Mouse anti-mouse b-actin: IRDye 680RD (red color). 
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Since megalin is predominantly expressed in renal proximal tubules, mouse renal 
proximal tubule cell (TKPTS; ATCC) was used to test the expression of megalin. However, 
megalin was not detected in TKPTS (Fig. 5.3). Although megalin-expressing cells can 
potentially be used for experiments of AGT and megalin interaction, the further megalin 
expression confirmation in other cells (e.g. HK-2 cell) and cell culture condition will need 
to be verified.  
 
Figure 5.3 TKPTS cells did not express megalin. 
TKPTS cell lysate was used for western blotting analysis. Rabbit anti-human megalin: 
IRDye 680RD (red color). Mouse anti-mouse b-actin: IRDye 800CW (green color). 
 
In addition, to solve the problem of recombinant AGT protein production, our 
collaborator, Dr. Vander Kooi in Molecular and Cellular Biochemistry at the University 
of Kentucky will try to use different cell expression systems to generate recombinant AGT 
with different mutations for the future studies.  
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5.3 Perspectives 
AGT is the only precursor of all angiotensin peptides, so how AGT is regulated is 
critical for many pathophysiological functions which mediated by angiotensin peptides. 
Moreover, targeting AGT acts as a potential therapeutic method of many angiotensin-
mediated diseases. For example, maternal liver-derived AGT inhibition by siRNA 
improved pre-eclampsia phenotypes, such as blood pressure and the fetus growth 
restriction [70]. In addition, liver-specific AGT inhibition by N-acetylgalactosamine 
(GalNAc)-conjugated antisense oligonucleotides (ASO) targeting AGT reduced blood 
pressure in spontaneously hypertensive rats fed an 8 % NaCl diet which is a hypertension 
model resistant to the RAS inhibitors and protected renal functions in rats salt-deprived 
which is a model activating renin production and activity [62], showing a promising roles 
of targeting AGT in treatment of hypertension and kidney injury. Therefore, to understand 
how AGT function and metabolism are regulated benefits the development of therapy by 
targeting AGT. Our previous paper demonstrates that AGT and megalin interactions 
regulate renal RAS homeostasis and development of atherosclerosis [57], indicating the 
pivotal roles of local renal RAS in AngII-mediated diseases. In our future study, 
understanding the potential interactions between AGT and megalin would provide 
evidence how AGT is regulated locally and how local RAS affects AngII-mediated 
diseases, which might facilitate the development of therapeutic treatment targeting tissue-
specific AGT in AngII-associated diseases.  
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